[go: up one dir, main page]

WO2024236325A1 - Procédé et produits pour caractériser un polynucléotide à l'aide d'un nanopore - Google Patents

Procédé et produits pour caractériser un polynucléotide à l'aide d'un nanopore Download PDF

Info

Publication number
WO2024236325A1
WO2024236325A1 PCT/GB2024/051301 GB2024051301W WO2024236325A1 WO 2024236325 A1 WO2024236325 A1 WO 2024236325A1 GB 2024051301 W GB2024051301 W GB 2024051301W WO 2024236325 A1 WO2024236325 A1 WO 2024236325A1
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
nanopore
cation
membrane
rubidium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/GB2024/051301
Other languages
English (en)
Inventor
Lukasz CISZEWSKI
Sebastien James DAVIS
Graham James HALL
Olle Alfred NORDESJO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Nanopore Technologies PLC
Original Assignee
Oxford Nanopore Technologies PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Nanopore Technologies PLC filed Critical Oxford Nanopore Technologies PLC
Priority to AU2024272217A priority Critical patent/AU2024272217A1/en
Publication of WO2024236325A1 publication Critical patent/WO2024236325A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing

Definitions

  • the present disclosure provides methods of characterising a polynucleotide as it translocates through a nanopore.
  • the disclosure also provides methods of operating a nanopore array.
  • the disclosure also provides novel kits and apparatuses for use in the methods of the disclosure.
  • nucleic acid sequencing allows the study of genomes and the proteins they encode and, for example, allows correlation between nucleic acid mutations and observable phenomena such as disease indications.
  • Nucleic acid sequencing can be used in evolutionary biology to study the relationship between organisms. Metagenomics involves identifying organisms present in samples, for example microbes in a microbiome, with nucleic acid sequencing allowing the identification of such organisms.
  • Nanopore sensing of polynucleotide analytes can reveal the identity and perform single molecule counting of the sensed analytes in real time, but can also provide information on their composition such as their nucleotide sequence, as well as the presence of characteristics such as base modifications, oxidation, reduction, decarboxylation, deamination and more. Nanopore sensing has the potential to allow rapid and cheap polynucleotide sequencing, providing single molecule sequence reads of polynucleotides of tens to tens of thousands bases length. Furthermore, the potential to create very long reads has a number of benefits over traditional next-generation sequencing technologies that produce short reads (typically ⁇ 300 bp). For example, in the context of whole genome sequencing, the longer reads produced by nanopore sensing allows easier assembly of DNA fragments, improved characterisation of repetitive genomic regions and identification of large structural variations.
  • Two of the essential components of polymer characterization using nanopore sensing are (1) the control of polymer movement through the pore and (2) the discrimination of the component building blocks as the polymer is moved through the pore.
  • nanopore sensing of analytes such as polynucleotides
  • Uncontrolled movement can prevent or impede accurate characterisation of the polynucleotides. For example, accurately distinguishing each nucleotide in a homopolymeric polynucleotide is problematic when the movement of the polynucleotide with respect to the pore is not controlled.
  • this may involve efficiently controlling the movement of the polynucleotide with respect to the detector used to characterise the polynucleotides, such as a nanopore, for example by controlling the movement of a polynucleotide with respect to a detector such as a nanopore by using a motor protein to control the movement of the polynucleotide.
  • a further aspect involves reducing unproductive characterisation of species which may be present in a sample but which are not the desired analyte. There is a need for such “unproductive characterisation” to be reduced.
  • blocking e.g. pore blocking
  • pore blocking may arise due to a variety of reasons, for example due to the formation of secondary structure by the polynucleotide on the side of the nanopore that is first contacted with the polynucleotide, the binding of co-factors or proteins to the polynucleotide on the side of the nanopore that is first contacted with the polynucleotide, or simply the speed at which the polynucleotide is translocated.
  • pore blocking is a key limiting factor on the amount of information that may be obtained from a nanopore array.
  • cation-mediated secondary structure may contribute to blocking of detector arrays (e.g. nanopore arrays).
  • detector arrays e.g. nanopore arrays.
  • conditions which decrease formation of secondary structure can be beneficially used to improve the quality of data that is obtained from a nanopore array.
  • the disclosure relates to methods of characterising a polynucleotide.
  • the polynucleotide is contacted with a nanopore, which has a first opening and a second opening.
  • a portion of the polynucleotide is translocated through the nanopore in the direction from the first opening to the second opening.
  • the portion of the polynucleotide that has translocated through the nanopore is then brought into contact with conditions that are present on the Side of nanopore having the second opening. The conditions decrease the formation of cation-mediated secondary structure by the portion of the polynucleotide that has translocated through the pore.
  • the portion of the polynucleotide is subsequently translocated through the nanopore in the direction from the second opening to the first opening.
  • One or more measurements that are characteristic of the polynucleotide are taken during the translocation of the polynucleotide through the nanopore to thereby characterise the polynucleotide.
  • the one or more measurements may be taken when the polynucleotide translocates through the nanopore in the direction from the first opening to the second opening and/or when the polynucleotide translocates through the nanopore in the direction from the second opening to the first opening.
  • the disclosure relates to methods of operating a nanopore array.
  • Each nanopore in the array has a first opening and a second opening.
  • a plurality of polynucleotides are contacted with the array.
  • the conditions under which the plurality of polynucleotides are contacted with the array lead to a portion of each polynucleotide translocating through the nanopores in the array in the direction from the first opening to the second opening, i.e. a portion of a first polynucleotide is translocated through a first nanopore in the direction from the first opening to the second opening, a portion of a second polynucleotide is translocated through a second nanopore in the direction from the first opening to the second opening, and so forth.
  • a method, of characterising a polynucleotide comprising:
  • the method comprises translocating the entire polynucleotide through the nanopore and taking one or more measurements during said translocation.
  • the method comprises repeating steps (b) to (d) multiple times.
  • the method comprises ejecting the polynucleotide from the first opening of the nanopore.
  • the one or more undesired characteristics include the inability of the polynucleotide to fully translocate through the nanopore in the first direction with respect to the nanopore.
  • the method comprises characterising a plurality of polynucleotides using a plurality of nanopores. In some embodiments, the plurality of nanopores are present in a nanopore array.
  • each nanopore in the array has a first opening and a second opening, the method comprising:
  • step (c) determining whether each polynucleotide translocated in step (b) has a desired characteristic
  • the method comprises taking one or more measurements characteristic of the polynucleotides in the plurality of polynucleotides during the translocation of the portion of each polynucleotide through the nanopore, thereby characterising the polynucleotides.
  • the method is performed at a temperature lower than the melting temperature of the cation-mediated secondary structure.
  • the cation-mediated secondary structure is a guanine tetrad or a G-quadruplex, preferably a G-quadruplex.
  • the one or more conditions comprise a salt that disrupts the stability of the cation-mediated secondary structure.
  • the one or more conditions comprise a metal salt that disrupts the stability of the cation-mediated secondary structure.
  • the metal salt comprises a cation selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 24- and Ca 2+ .
  • the metal salt comprise comprises a Rb + cation.
  • the metal salt comprises (i) rubidium ferricyanide and/or rubidium ferrocyanide, and/or (ii) rubidium chloride.
  • the metal salt comprises a Na + cation. In some embodiments, the metal salt comprises sodium ferricyanide and/or sodium ferrocyanide. In some embodiments, the salt comprises an ammonium cation (NH4 + ). In some embodiments of the above methods, the conditions are substantially free of K + .
  • the polynucleotide, or each polynucleotide in the plurality of the polynucleotides has a length of 100 nucleotides or more. In some embodiments of the above methods, the polynucleotide has a length of 5000 nucleotides or more, or the polynucleotides in the plurality of polynucleotides have an average length of 5000 nucleotides or more.
  • the method comprises controlling the movement of the or each polynucleotide with respect to the nanopore in the first direction using a polynucleotide-handling protein.
  • the polynucleotide- handling protein is or comprises a helicase, translocase or helicase-nuclease complex.
  • the nanopore is a protein pore, a solid state pore or a DNA origami pore, preferably wherein the nanopore is a transmembrane protein pore.
  • the one or more characteristics comprises (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide and (v) whether or not the polynucleotide is modified.
  • ejecting the polynucleotide from the nanopore comprises applying a force across the nanopore.
  • the force comprises a voltage potential applied across the nanopore.
  • the method comprises applying a voltage potential across the nanopore via one or more platinum electrodes.
  • kits for characterising a polynucleotide comprising (a) a nanopore in a membrane; and (b) a solution comprising one or more metal salts selected from the group consisting of one or more rubidium salts, sodium ferricyanide and sodium ferrocyanide.
  • the one or more metal salts are selected from the group consisting of (i) rubidium ferricyanide and/or rubidium ferrocyanide, (ii) rubidium chloride, and/or (iii) sodium ferricyanide and sodium ferrocyanide.
  • an apparatus for characterising a polynucleotide comprising (a) an array of nanopores in a membrane; and (b) a solution comprising one or more metal salts in contact with the membrane, wherein the one or more metal salts are selected from the group consisting of one or more rubidium salts, sodium ferricyanide and sodium ferrocyanide.
  • the one or more metal salts are selected from the group consisting of (i) rubidium ferricyanide and/or rubidium ferrocyanide, (ii) rubidium chloride, and (iii) sodium ferricyanide and sodium ferrocyanide.
  • the array is an array of individually addressable elements, wherein each independently addressable element of the array comprises a cis and a trans chamber connected by an electrical communication means, wherein said cis and trans chambers are separated by the membrane, and the membrane of each independently addressable element comprises a single nanopore.
  • the cis and the trans chamber each comprise the solution.
  • the trans chamber comprises the solution, and the cis chamber comprises a different solution comprising one or more metal salts.
  • the apparatus comprises a polynucleotide handling enzyme on the cis side of the membrane.
  • the independently addressable elements of the array share a common cis chamber.
  • each independently addressable element has a trans chamber separate from the trans chambers of other independently addressable elements of the array.
  • the apparatus comprises a voltage source connected to electrodes, wherein the voltage source and electrodes are configured to apply an electric field between the cis and the trans chambers.
  • the apparatus comprises a digital logic circuit associated with the nanopores of the independently addressable elements of the array of independently addressable elements.
  • the one or more metal salts are selected from the group consisting of one or more rubidium salts, sodium ferricyanide and sodium ferrocyanide.
  • the one or more metal salts are selected from the group consisting of (i) rubidium ferricyanide and/or rubidium ferrocyanide, (ii) rubidium chloride, and (iii) sodium ferricyanide and sodium ferrocyanide.
  • Figure 1 Non-limiting schematic showing the translocation of a polynucleotide from a first side (e.g. the cis side) of a nanopore to a second side (e.g. the trans side) of a detector such as a nanopore.
  • a first side e.g. the cis side
  • a second side e.g. the trans side
  • secondary structure is formed by the polynucleotide on the trans side of the nanopore.
  • the top schematic no issue is encountered when the polynucleotide translocates from the cis to the trans side of the pore, and further polynucleotides may be captured by the nanopore.
  • an issue is encountered that prevents the polynucleotide from fully translocating from the cis to the trans side of the nanopore, resulting in pore blocking.
  • FIG. 1 Estimated output (MB) over time normalised to 1500 nanopores.
  • Y-axis indicates the cumulative sum (y-axis; MB) of data collected from a sample comprising human genomic DNA 30 kb in length over time.
  • Control refers to a buffer comprising a potassium salt on the cis and trans side of the nanopores.
  • Na refers to a buffer comprising a sodium salt on the cis and trans side of the nanopores.
  • MB Estimated output (MB) over time normalised by the number of starting channels.
  • Y-axis indicates the cumulative sum (y-axis; MB) of data collected from a sample comprising a polynucleotide comprising a sequence known to form a G-quadruplex over time.
  • Control refers to a buffer comprising a potassium salt on the cis and trans side of the nanopores.
  • Na and sodium_cistrans refer to a buffer comprising a sodium salt on the cis and trans side of the nanopores.
  • Sodium cis refers to a buffer comprising a potassium salt on the cis side of the nanopores and a sodium salt on the trans side of the nanopores.
  • FIG. 4 Melting temperature of a G-quadruplex in the presence of different salts, as determined by fluorescence spectroscopy.
  • the 3’ and 5’ ends of a polynucleotide comprising a G-quadruplex structure were attached to a quencher and a fluorophore such that the fluorescence was quenched when the G-quadruplex was formed around the cation.
  • the quenching of the fluorophore was reduced.
  • FIG. 5 Graph showing normalised fluorescence [-] vs temperature [°C] for the same G-quadruplex-forming polynucleotide in different ionic solutions (potassium, sodium, and rubidium). Cation type has a large effect on G-quadruplex stability. From left to right, the curves depicted are: Rb + , Na + (150 mM), Na + (210 mM), K + .
  • Figure 7 A: Sequencing Output over time comparing rubidium salt flow cells to control potassium salt flow cells. Potassium salt flow cells only were washed and reloaded at 22 hours. Total sequencing outputs remain similar.
  • B Channel loss over time as a percentage of starting pores. Each line represents one flow cell. Recovery of pores at 22 hours for the potassium flow cells following wash and reload can be seen. The rate of channel loss for the rubidium salt flow cells is less than that for the potassium salt flow cells. This leads to better maintained throughput over time, leading to similar levels of output as in Fig. 7A.
  • Figure 8 Output over time for the same ULK114 human genomic DNA sample with potassium salts and rubidium salts each with two nuclease washes and reloads at approximately 24 hours and 48 hours. Increase in sequencing output is +46% for the rubidium salts.
  • B N50 of the ULK114 human genomic sample for both flow cell types, showing that both had read length N50s above 100 kilobases.
  • a polynucleotide includes two or more polynucleotides
  • reference to “a polynucleotide-handling enzyme” includes two or more such polynucleotide-handling enzymes
  • reference to “a nanopore” includes two or more nanopores and the like.
  • the methods, uses and products of the invention equally relate to the use of a detector in place of a nanopore.
  • the methods, uses and products provided herein are amenable to detectors including (i) a zero-mode waveguide, (ii) a field-effect transistor, optionally a nanowire field-effect transistor; (iii) an AFM tip; (iv) a nanotube, optionally a carbon nanotube and (v) a nanopore.
  • the disclosed methods, uses and products are particularly amenable to applications in which a polynucleotide is moved through a detector or through a structure containing a detector, e.g. a well in a detector chip.
  • “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ⁇ 20 % or ⁇ 10 %, more preferably ⁇ 5 %, even more preferably ⁇ 1 %, and still more preferably ⁇ 0.1 % from the specified value, as such variations are appropriate to perform the disclosed methods.
  • Nucleic acids may be manufactured synthetically in vitro or isolated from natural sources. Nucleic acids may further include modified DNA or RNA, for example DNA or RNA that has been methylated, or RNA that has been subject to post-translational modification, for example 5’-capping with 7-methylguanosine, 3’-processing such as cleavage and polyadenylation, and splicing.
  • modified DNA or RNA for example DNA or RNA that has been methylated, or RNA that has been subject to post-translational modification, for example 5’-capping with 7-methylguanosine, 3’-processing such as cleavage and polyadenylation, and splicing.
  • Nucleic, acids may also include synthetic nucleic acids (XNA), such as hexitol nucleic acid (HNA), cyclohexene nucleic acid (CeNA), threose nucleic acid (TNA), glycerol nucleic acid (GNA), locked nucleic acid (LNA) and peptide nucleic acid (PNA).
  • Sizes of nucleic acids also referred to herein as “polynucleotides” are typically expressed as the number of base pairs (bp) for double stranded polynucleotides, or in the case of single stranded polynucleotides as the number of nucleotides (nt).
  • oligonucleotides typically called “oligonucleotides” and may comprise primers for use in manipulation of DNA such as via polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • amino acid in the context of the present disclosure is used in its broadest sense and is meant to include organic compounds containing amine (NH2) and carboxyl (COOH) functional groups, along with a side chain (e.g., a R group) specific to each amino acid.
  • NH2 amine
  • COOH carboxyl
  • side chain e.g., a R group
  • the amino acids refer to naturally occurring L examino acids or residues.
  • amino acid further includes D- amino acids, retro-inverso amino acids as well as chemically modified amino acids such as amino acid analogues, naturally occurring amino acids that are not usually incorporated into proteins such as norleucine, and chemically synthesised compounds having properties known in the art to be characteristic of an amino acid, such as p-amino acids.
  • amino acid analogues naturally occurring amino acids that are not usually incorporated into proteins such as norleucine
  • chemically synthesised compounds having properties known in the art to be characteristic of an amino acid such as p-amino acids.
  • analogues or mimetics of phenylalanine or proline which allow the same conformational restriction of the peptide compounds as do natural Phe or Pro, are included within the definition of amino acid.
  • Such analogues and mimetics are referred to herein as "functional equivalents" of the respective amino acid.
  • leader and “leader sequence” are used interchangeably herein.
  • polypeptide and “peptide” are interchangeably used herein to refer to a polymer of amino acid residues and to variants and synthetic analogues of the same. Thus, these terms apply to amino acid polymers in which one or more amino acid residues is a synthetic non-naturally occurring amino acid, such as a chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally-occurring amino acid polymers.
  • Polypeptides can also undergo maturation or post-translational modification processes that may include, but are not limited to: glycosylation, proteolytic cleavage, lipidization, signal peptide cleavage, propeptide cleavage, phosphorylation, and such like.
  • a peptide can be made using recombinant techniques, e.g., through the expression of a recombinant or synthetic polynucleotide.
  • a recombinantly produced peptide it typically substantially free of culture medium, e.g., culture medium represents less than about 20 %, more preferably less than about 10 %, and most preferably less than about 5 % of the volume of the protein preparation.
  • the term “protein” is used to describe a folded polypeptide having a secondary or tertiary structure.
  • the protein may be composed of a single polypeptide, or may comprise multiple polypeptides that are assembled to form a multimer.
  • the multimer may be a homooligomer, or a heterooligmer.
  • the protein may be a naturally occurring, or wild type protein, or a modified, or non-naturally, occurring protein.
  • the protein may, for example, differ from a wild type protein by the addition, substitution or deletion of one or more amino acids.
  • a “variant” of a protein encompass peptides, oligopeptides, polypeptides, proteins and enzymes having amino acid substitutions, deletions and/or insertions relative to the unmodified or wild-type protein in question and having similar biological and functional activity as the unmodified protein from which they are derived.
  • amino acid identity refers to the extent that sequences are identical on an amino acid- by-amino acid basis over a window of comparison.
  • a "percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Vai, Leu, He, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gin, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
  • the identical amino acid residue e.g., Ala, Pro, Ser, Thr, Gly, Vai, Leu, He, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gin, Cys and Met
  • a “variant” has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% complete sequence identity to the amino acid sequence of the corresponding wild-type protein. Sequence identity can also be to a fragment or portion of the full-length polynucleotide or polypeptide. Hence, a sequence may have only 50 % overall sequence identity with a full-length reference sequence, but a sequence of a particular region, domain or subunit could share 80 %, 90 %, or as much as 99 % sequence identity with the reference sequence.
  • wild-type refers to a gene or gene product isolated from a naturally occurring source.
  • a wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designed the “normal” or “wild-type” form of the gene.
  • modified”, “mutant” or “variant” refers to a gene or gene product that displays modifications in sequence (e.g., substitutions, truncations, or insertions), post- translational modifications and/or functional properties (e.g., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
  • methionine (M) may be substituted with arginine (R) by replacing the codon for methionine (ATG) with a codon for arginine (CGT) at the relevant position in a polynucleotide encoding the mutant monomer.
  • Methods for introducing Or substituting non-naturally-occurring amino acids are also well known in the art.
  • non- naturally-occurring amino acids may be introduced by including synthetic aminoacyl- tRNAs in the IVTT system used to express the mutant monomer. Alternatively, they may be introduced by expressing the mutant monomer in E.
  • coli that are auxotrophic for specific amino acids in the presence of synthetic (i.e. non-naturally-occurring) analogues of those specific amino acids. They may also be produced by naked ligation if the mutant monomer is produced using partial peptide synthesis. Conservative substitutions replace amino acids with other amino acids of similar chemical structure, similar chemical properties or similar side-chain volume.
  • the amino acids introduced may have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality or charge to the amino acids they replace.
  • the conservative substitution may introduce another amino acid that is aromatic or aliphatic in the place of a pre-existing aromatic or aliphatic amino acid.
  • Conservative amino acid changes are well-known in the art and may be selected in accordance with the properties of the 20 main amino acids as defined in Table 1 below. Where amino acids have similar polarity, this can also be determined by reference to the hydropathy scale for amino acid side chains in Table 2.
  • a mutant or modified protein, monomer or peptide can also be chemically modified in any way and at any site.
  • a mutant or modified monomer or peptide is preferably chemically modified by attachment of a molecule to one or more cysteines (cysteine linkage), attachment of a molecule to one or more lysines, attachment of a molecule to one or more non-natural amino acids, enzyme modification of an epitope or modification of a terminus. Suitable methods for carrying out such modifications are well-known in the art.
  • the mutant of modified protein, monomer or peptide may be chemically modified by the attachment of any molecule.
  • the mutant of modified protein, monomer or peptide may be chemically modified by attachment of a dye or a fluorophore.
  • the disclosure relates to a method of characterising a polynucleotide as it translocates through a nanopore having a first opening and a second opening.
  • a portion of the polynucleotide translocates in a first direction with respect to the nanopore, wherein the first direction is from the first opening to the second opening.
  • the portion of the polynucleotide translocates through the nanopore in a second direction with respect to the nanopore, wherein the second direction is from the second opening to the first opening.
  • the portion of the polynucleotide that translocates through the nanopore is contacted with one or more conditions which decrease formation of cation-mediated secondary structure.
  • the inventors believe that the formation of secondary structure by the portion of the polynucleotide that has translocated through the pore may prevent the movement of the polynucleotide in the second direction, such that if the pore becomes blocked by a polynucleotide, thus preventing translocation of the polynucleotide from the first opening to the second opening, ejecting the polynucleotide by reversing the direction of movement of the polynucleotide through the pore is also impeded. This is described in Figure 1.
  • the inventors consider that this phenomenon could account for a substantial portion of the observed decrease in nanopore array lifetimes and limited nanopore efficiency, particularly when addressing long nanopores. More specifically, (without being bound by theory) the inventors consider that cation-mediated secondary structure may be responsible for as much as 30-40% of instances where a pore becomes “permanently blocked”, i.e. is unable to be unblocked by reversing the direction of movement of a polynucleotide through a pore.
  • the inventors have now found that by contacting the portion of the polynucleotide that has translocated through the pore with conditions which decrease formation of cation- mediated secondary structure by the polynucleotide, a greater proportion of pore blockages are able to be unblocked.
  • the functional lifetime of nanopore arrays can thus be increased and the characterisation data obtained when a nanopore array is used to characterise a sample of polynucleotides can be improved.
  • a method of characterising a target polynucleotide comprising contacting the polynucleotide with a nanopore having a first opening and a second opening; translocating a portion of the polynucleotide through the nanopore in a first direction with respect to the nanopore, wherein the first direction is from the first opening to the second opening; contacting the translocated portion of the polynucleotide with one or more conditions which decrease formation of cation-mediated secondary structure; translocating the polynucleotide in a second direction with respect to the nanopore, wherein the second direction is from the second opening to the first opening; and taking one or more measurements characteristic of the polynucleotide during the translocation of the polynucleotide through the nanopore, thereby characterising the polynucleotide.
  • the method comprises translocating the entire polynucleotide through the nanopore and taking one or more measurements during said translocation. In some embodiments, if the measurements characteristic of the polynucleotide are indicative of one or more undesired characteristics of the polynucleotide, the method comprises ejecting the polynucleotide from the first opening of the nanopore. This enables the method to be used in an “adaptive sampling” approach to characterisation of a polynucleotide. If the measurement of a portion of the polynucleotide is indicative of a desired characteristic, e.g.
  • the measurement can continue. If the measured of a portion of the polynucleotide is indicative of an undesired characteristic, e.g. a genomic region that is not of interest, the polynucleotide can be ejected from the nanopore to allow a further polynucleotide to be characterised. The methods reduce pore blocking in both cases.
  • the method may comprise repeating the steps of translocating a portion of the polynucleotide through the nanopore in a first direction with respect to the nanopore, wherein the first direction is from the first opening to the second opening; contacting the translocated portion of the polynucleotide with one or more conditions which decrease formation of cation-mediated secondary structure; and translocating the polynucleotide in a second direction with respect to the nanopore, wherein the second direction is from the second opening to the first opening.
  • the target polynucleotide may oscillate with respect to the detector (i.e. it may be “flossed” with respect to the first and second openings of the detector). This “flossing” allows the target polynucleotide to be repeatedly characterised. In some embodiments this allows the accuracy of the characterisation information to be increased. This is described in more detail in WO 2021/255476, the entire contents of which are hereby incorporated by reference.
  • the undesired characteristics of a polynucleotide may include the inability of the polynucleotide to fully translocate though the nanopore in the first direction with respect to the nanopore. This characteristic is the detection of a blocked nanopore, which is undesirable as a blocked nanopore prevents the nanopore from characterising further polynucleotides.
  • the method of characterising a polynucleotide enables a nanopore to be used to characterise more polynucleotides than would otherwise be possible (due to blockages).
  • the method comprises characterising a plurality of polynucleotides using a plurality of nanopores.
  • the plurality of nanopores are present in a nanopore array. The method of characterising a polynucleotide extends the lifetime of the array by reducing nanopore blocking and therefore increasing the availability of nanopores in an array for further characterisation, as shown in Figures 2 and 3.
  • the disclosure relates to methods of operating a nanopore array.
  • Each nanopore in the array has a first opening and a second opening.
  • the method comprises contacting the array with a plurality of polynucleotides under conditions such that a portion of each polynucleotide translocates through the array in a first direction with respect to the nanopores in the array, wherein the first direction is from the first opening to the second opening.
  • the portion of the polynucleotide that translocates through the nanopore is contacted with one or more conditions which decrease formation of cation-mediated secondary structure, as discussed above with respect to the method of characterising a polynucleotide.
  • the method comprises determining whether each polynucleotide that has been translocated has a desired characteristic, and ejecting polynucleotides which do not have the desired characteristic by translocating the polynucleotide in a second direction with respect to the nanopores in the array, wherein the second direction is from the second opening to the first opening.
  • the desired characteristic may be the ability of the polynucleotide to fully translocate though the nanopore in the first direction with respect to the nanopore.
  • the efficiency of the nanopore array is improved as time is not spent on measuring characteristics of an undesired polynucleotide. Furthermore, the improved ability to eject polynucleotides that do not have desired characteristics, as a result of the conditions which decrease formation of cation-mediated secondary structure, improves the lifetime of the nanopore array, as discussed above.
  • the method is performed at a temperature lower than the melting temperature of the cation-mediated secondary structure.
  • the stability of cation- mediated secondary structure can be determined using a fhiorophore-quencher approach.
  • the inventors have determined that under typical running conditions of a nanopore involving a potassium salt, the melting temperature of the exemplary cation-mediated secondary structures may be elevated.
  • the inventors have further determined that conditions which decrease formation of cation-mediated secondary structure can depress the melting temperature of the cation-mediated secondary structure.
  • the melting temp of an exemplary G quadruple* was determined to be approximately 65 °C, whereas under the conditions identified herein as decreasing formation of cation-mediated secondary structure, the melting temperature of the cation-mediated secondary structure was approximately 50°C.
  • the melting temperature of an exemplary G quadruple* in the presence of potassium ions was reduced by approximately 10°C or 20°C under conditions comprising Na + or Rb + cations, respectively.
  • the inventors have found that benefits of decreased pore blocking, improved array lifetime and improved data characterisation do not require that the melting temperature of the cation-mediated secondary structure be decreased below the operational temperature of the methods.
  • the inventors consider that the methods disclosed herein provide beneficial effects as disclosed herein even when such methods are operated at temperatures at which cation-mediated secondary structure may still form.
  • the methods may be carried out at from 0 °C to 100 °C, such as from 10 °C to 90 °C, from 15 °C to 80 °C, from 17 °C to 60 °C, from 18 °C to 55 °C, from 19 °C to 50 °C, or from 20 °C to 45 °C.
  • the cation mediated secondary structure has a melting temperature of more than 50 °C, such as more than 55 °C, e.g. more than 60 °C; and the methods are carried out below the melting temperature of the cation mediated secondary structure, e.g. below 60 °C, such as below 55 °C, e.g. below 50 °C.
  • the methods are typically carried out at a temperature that supports enzyme function, such as a temperature of from about 20 °C to about 50 °C such as from about 30 °C to about 45 °C e.g. from about 34 °C to about 40 °C, e.g. about 31, 32, 33, 34, 35, 36, 37, 38, or 39 °C.
  • a temperature that supports enzyme function such as a temperature of from about 20 °C to about 50 °C such as from about 30 °C to about 45 °C e.g. from about 34 °C to about 40 °C, e.g. about 31, 32, 33, 34, 35, 36, 37, 38, or 39 °C.
  • the melting temperature of the cation-mediated secondary structure when contacted with the one or more conditions is reduced.
  • the melting temperature is reduced by at least 5 °C, such as at least 10 °C, at least 15 °C, or at least 20 °C.
  • the reduction in melting temperature may be calculated in comparison to the melting temperature of the cation-mediated secondary structure when contacted with a reference condition.
  • a skilled person can readily determine suitable reference conditions depending on the condition being altered to decrease cation-mediated secondary structure formation.
  • the reduction in melting temperature is calculated using a thrombin-binding aptamer comprising a G-quadruplex, as known in the art and as discussed in examples 1 and 2.
  • the total read output of the nanopore is increased. In some embodiments, the total read output of the nanopore is increased by at least 10%, such as at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 37%, at least 40%, at least 45%, at least 46%, at least 50%, or at least 55%. In some embodiments, the increase in total read output may be calculated in comparison to the total read output of a nanopore comprising a reference condition. A skilled person can readily determine suitable reference conditions depending on the condition being altered to increase total read output of the nanopore. In some embodiments, total read output is calculated over 24, 48 or 72 hours.
  • the loss of hanopores in an array is reduced.
  • the term “loss” is intended to refer to a nanopore that is not capable of taking one or more measurements characteristic of a polynucleotide during the translocation of the polynucleotide through the nanopore.
  • the loss of a nanopore is caused by blocking of the nanopore by the cation-mediated secondary structure of the polynucleotide.
  • the loss of nanopores in an array is reduced by at least 1%, such as at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, or at least 20%.
  • the loss of nanopores in an array may be calculated in comparison to the loss of nanopores in an array comprising a reference condition.
  • a skilled person can readily determine suitable reference conditions depending on the condition being altered to reduce the loss of nanopores in an array.
  • the loss of nanopores in an array is calculated over 24, 48 or 72 hours, as discussed in example 4.
  • the reference condition comprises the presence of a potassium salt.
  • the reference conditions may promote formation of potassium cation-mediated secondary structure, such as the formation of potassium cation-mediated G-tetrad and/or G- quadruplex.
  • the reference condition is the presence of 150mM potassium ferricyanide, 150mM potassium ferrocyanide, 25mM potassium phosphate, pH8 at 34°C.
  • the first and second openings may be referred to as the cis and trans openings of the nanopore.
  • the first opening is the cis opening and the second opening is the trans opening, but in some embodiments the first opening is the trans opening and the second opening is the cis opening, respectively.
  • the notation “cis” and “trans” openings in nanopores is routine in the art.
  • the cis opening of a nanopore typically faces the cis chamber of a nanopore device such as an apparatus as described herein having cis and trans chambers, and the trans opening typically faces the trans chamber.
  • the nanopore is present in a structure such as a membrane having a cis side and a trans side.
  • the cis side of the structure or membrane is typically the side of the membrane that is first contacted with the polynucleotide, i.e. the side of a membrane to which a sample comprising the polynucleotide is added.
  • the trans side of the membrane is typically the other side of the membrane from which the polynucleotide is first contacted with the membrane.
  • the first opening of the nanopore is at the cis side of the membrane and the second opening of the nanopore is at the trans side.
  • the first direction is from the cis side of the membrane to the trans side of the nanopore (or structure or membrane comprising the nanopore) and the second direction is from the trans side of the nor (or the structure or membrane comprising the nanopore) to the cis side of the membrane.
  • the method comprises contacting the translocated portion of the polynucleotide with one or more conditions which decrease formation of cation-mediated secondary structure on the trans side of the membrane.
  • the first opening of the nanopore is at the trans side of the nanopore (or structure or membrane comprising the nanopore) and the second opening of the nanopore is at the cis side of the nanopore (or structure or membrane comprising the nanopore).
  • the first direction is from the trans side of the membrane to the cis side of the membrane and the second direction is from the cis side of the membrane to the trans side of the membrane.
  • the method comprises contacting the translocated portion of the polynucleotide with one or more conditions which decrease formation of cation-mediated secondary structure on the cis side of the membrane.
  • the trans side of the membrane comprises the one or more conditions which decrease formation of cation-mediated secondary structure.
  • the conditions On the cis side of the membrane may or may not decrease formation of cation-mediated secondary structure.
  • the one or more conditions which decrease formation of cation-mediated secondary structure are on both the cis and trans sides of the membrane.
  • the conditions on the cis side of the membrane comprises one or more conditions that decrease formation of cation- mediated secondary structure.
  • the conditions on the cis side of the membrane do not comprise conditions that decrease formation of cation-mediated secondary structure.
  • the methods comprise contacting a portion of a polynucleotide that has been translocated through the pore with one or more conditions that decrease formation of cation-mediated secondary structure.
  • the secondary structure comprises a hydrogen-bonded plurality of polynucleotides.
  • the hydrogen bonded polynucleotides form a planar substructure.
  • a plurality of planar hydrogen-bonded substructures are stabilised by charge interactions.
  • a plurality of such substructures may be stabilised by ionic binding to a metal cation. Such structures may thus be characterised as being cation-mediated.
  • the secondary structure comprises a plurality of guanosine nucleotides.
  • the secondary structure is formed from a polynucleotide sequence rich in guanosine nucleotides, such as sequence at least 15 nucleotides in length or more and comprising 50% or more guanine bases.
  • the cation-mediated secondary structure comprises a tetrad and/or a quadruplex.
  • a tetrad is formed by four nucleotide residues, typically all of the same time, in a planar arrangement.
  • a quadruplex is compared of at least two tetrads stacked upon one another.
  • the cation-mediated secondary structure comprises a G-tetrad and/or a G- quadruplex.
  • a G-tetrad is formed by four guanosine nucleotides.
  • a G-quadruplex is formed by at least two stacked G-tetrads, i.e.
  • the G-quadruplex comprises at least two G-tetrads, such as at least three G-tetrads or at least four G-tetrads.
  • G-tetrads and G-quadruplexes are polynucleotide sequences that are rich in guanine and are capable of forming a four- stranded structure.
  • Four guanine bases can associate through Hoogsteen hydrogen bonding to form a square planar structure called a guanine tetrad, and two or more guanine tetrads can stack on top of each other to form a G-quadruplex.
  • the quadruplex structure is further stabilized by the presence of a cation, especially potassium, which sits in a central channel between each pair of tetrads.
  • a cation especially potassium
  • Forming G-quadruplexes is well known in the art (Marathias and Bolton, Nucleic Acids Research, 2000; 28(9): 1969-1977; Kankia and Marky, J. Am. Chem. Soc. 2001, 123, 10799-10804; andMarusic et al., Nucleic Acids Research, 2012, 1- 11).
  • the G-quadruplex may be a parallel G-quadruplex, an anti- parallel G-quadruplex or a hybrid G-quadruplex.
  • the one or more quadruplexes comprise the sequence Ga followed by Nb followed by Gc followed by Nd followed by Ge followed by Nf followed by Gg, wherein G is a nucleotide comprising guanine, wherein a, c, e and g are independently selected from 1, 2, 3, 4 and 5, wherein N is any nucleotide and wherein b, d and f are from 2 to 50.
  • G is a nucleotide comprising guanine
  • a, c, e and g are independently selected from 1, 2, 3, 4 and 5, wherein N is any nucleotide and wherein b, d and f are from 2 to 50.
  • the values of a, c, e and g may be identical.
  • G is guanosine monophosphate (GMP), cyclic guanosine monophosphate (cGMP), deoxyguanosine monophosphate (dGMP), dideoxyguanosine monophosphate, N2-methyl- GMP, N2-methyl-cGMP, N2-methyl-dGMP, N2-methyl-dideoxyguanosine monophosphate, N2-methyl-06-methyl-GMP, N2-methyl-06-methyl-cGMP, N2-methyl- 06-methyl-dGMP, N2-methyl-06-methyl-dideoxyguanosine monophosphate, 2’-O-methyl- GMP, 2’-O-methyl-cGMP, 2’-O-methyl-dGMP, 2’-O-methyl-dideoxyguanosine monophosphate, 6-thio-GMP, 6-thio-cGMP, 6-thio-dGMP, 6-thio-dideoxyguanosine monophosphate, 7-methyl-GMP, 7-methyl-cGMP, 7-methyl-
  • a G-quadruplex comprises the sequence set out by the formula G m X n G m X o G m X p G m , wherein m is the number of G residues of each vertex of the Q quadruplex, and Xn, Xo and Xp can be any combination of residues, including G, forming the loops between the vertices, m is therefore equal to the number of G-tetrads in the G-quadruplex.
  • a G-quadruplex comprises at least 60% sequence identity to the sequence GGTTGGTGTGGTTGG (SEQ ID NO: 9), such as at least 70%, at least 80%, at least 90% or 100% sequence identity to the sequence GGTTGGTGTGGTTGG (SEQ ID NO: 9).
  • the methods comprise decreasing formation of the cation-mediated secondary structure.
  • the conditions may decrease formation of the cation-mediated secondary structure by any amount, such by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%.
  • the methods comprise decreasing stability of the cation-mediated secondary structure.
  • the conditions may decrease the stability of the cation-mediated secondary structure by any amount, such by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%.
  • the decrease of cation-mediated secondary structure formation or stability is typically compared to a reference condition.
  • a reference condition comprises the presence of a potassium salt.
  • the reference conditions may promote formation of potassium cation-mediated secondary structure, such as the formation of potassium cation- mediated G-tetrad and/or G-quadruplex.
  • the reference condition is the presence of the polynucleotide and 150mM potassium ferricyanide, 150mM potassium ferrocyanide, 25mM potassium phosphate, pH8 at 34°C.
  • a decreased in the formation of the cation-mediated structure may be determined by any means known to the skilled person, for example by identifying the melting temperature of the cation-mediated structure in the one or more conditions and in the reference condition. This is exemplified in Figures 4 and 5.
  • the methods comprise contacting a portion of a polynucleotide that has been translocated through the pore with one or more conditions that decrease formation of cation-mediated secondary structure.
  • the methods comprise contacting a portion of a polynucleotide that has been translocated through the pore with two or more conditions that decrease formation of cation-mediated secondary structure, such as three or more, or four or more conditions that decrease formation of cation-mediated secondary structure.
  • the first direction is from the cis side of the membrane to the trans side of the membrane
  • the one or more conditions are typically on the trans side of the membrane.
  • the cis side of the membrane may also comprise one or more conditions that decrease formation of cation mediated secondary structure.
  • the first direction is from the trans side of the membrane to the CM side of the membrane
  • the one or more conditions are typically on the cis side of the membrane.
  • the trans side of the membrane may also comprise one or more conditions that decrease formation of cation mediated secondary structure.
  • the conditions include, for example, salt-type, salt concentration, temperature, presence or absence of one or more oligonucleotides, and/or pH.
  • the conditions comprise an increased temperature, e.g. when compared to a reference condition.
  • the method is operated at an increased running temperature, which may decrease the formation and/or stability of cation-mediated secondary structures.
  • a suitable reference temperature may be about 34°C, and in some embodiments, the increased temperature is about 35°C or higher, such as about 35°C to about 70°C, e.g. about 35 °C to about 60°C, such as about 40°C to about 55°C or about 40°C to about 50°C.
  • the conditions comprise an altered pH, e.g. when compared to reference conditions.
  • a suitable reference pH is about pH 8.
  • the operational pH is about pH 7 or less, such as from about pH 2 to about pH 7 or about pH 3 to about pH 6.
  • the operational pH is about pH 9 or more, such as from about pH 9 to about pH 11.
  • the conditions comprise one or more control polynucleotides.
  • the one or more control polynucleotides hybridise with a portion of the sequence that is capable of forming cation-mediated secondary structure.
  • the one or more control polynucleotides hybridise with a portion of the sequence that is capable of forming a G-tetrad and/or a G-quadruplex.
  • the one or more control polynucleotides are the reverse complement of the portion of the sequence that is capable of forming cation-mediated secondary structure.
  • the portion of the sequence to which the one or more control polynucleotide hybridise may be at least 20% of the sequence that is capable of forming cation-mediated secondary structure, such as at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% of the sequence that is capable of forming cation-mediated secondary structure.
  • the one or more control polynucleotides are at least about 4 nucleotides in length, such as at least about 5, at least about 10, at least about 15, at least about 20, or at least about 30 nucleotides in length.
  • the one or more control polynucleotides are from about 4- 30 nucleotides in length, such as from about 5-25, e.g. from about 10-20 or about 12-16 nucleotides in length.
  • the conditions comprise a salt, such as a salt comprising an ammonium cation (NH4 + ) and/or a metal salt.
  • a salt such as a salt comprising an ammonium cation (NH4 + ) and/or a metal salt.
  • the salt disrupts the formation of the cation-mediated secondary structure.
  • the salt disrupts the stability of the cation-mediated secondary structure.
  • the salt may comprise one or more cations as described herein.
  • the salt comprises an ammonium cation (NH4 + ). Any suitable anion may be used in the salt.
  • Anions include fluoride, chloride, bromide, iodide, acetate, carbonate, citrate, phosphate, sulphite, sulphate, nitrite, ferricyanide and ferrocyanide.
  • the salt comprises one or more anions selected from the group consisting of chloride, ferricyanide and ferrocyanide.
  • the one or more anions comprise chloride.
  • the one or more anions comprise ferricyanide and ferrocyanide.
  • the salt comprises ammonium ferricyanide and/or ammonium ferrocyanide, typically a mixture of ammonium ferricyanide and ammonium ferrocyanide.
  • the salt comprises ammonium chloride.
  • the salt may comprise a mixture of anions described above, such as a mixture of ferricyanide, ferrocyanide and chloride anions.
  • the salt comprises (i) ammonium chloride and (ii) ammonium ferricyanide and/or ammonium ferrocyanide, typically a mixture of ammonium ferricyanide and ammonium ferrocyanide.
  • the conditions comprise a salt comprising an ammonium cation and a metal salt, as described herein.
  • the metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 24- and Ca 2+ , as described herein, such as (i) as a chloride salt and/or (ii) as a ferricyanide salt and/or a ferrocyanide salt, typically as a mixture of a ferricyanide salt and ferrocyanide salt
  • the concentration of the salt is from about 0.01 to about 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M. In some embodiments, the concentration of the salt is about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M. Where the salt is a mixture of two or more salts, the total concentration of the salts in the mixture may be from 0.01 to 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M.
  • the total concentration of the salt is about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M.
  • the concentration of the salts in the mixture are identical.
  • the concentration of the salts in the mixture are not identical.
  • the concentration of the salts may comprise a ratio of 1 : 1.5, 1:2, 1 :2.5, 1 :3, 1 :3.5, 1 :4 or 1 :5.
  • the salt comprises an ammonium cation and the concentration of the salt is from 0.01 to 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M, such as about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M.
  • the salt comprises a mixture of a ferricyanide salt and ferrocyanide salt, and the total concentration of the salts in the mixture is from 0.01 to 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M, such as about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M.
  • the conditions comprise a metal salt.
  • the metal salt disrupts the formation of the cation-mediated secondary structure.
  • the metal salt disrupts the stability of the cation-mediated secondary structure.
  • the metal salt comprises one or more monovalent or divalent metal salts. In some embodiments, the metal salt comprises one or more monovalent metal salts. In some embodiments, the metal salt does not comprise a potassium salt. In some embodiments, the metal salt does not comprise a potassium salt or a magnesium salt. In some embodiments, the metal salt comprises one or more cations having a dehydrated ionic diameter that is larger than the dehydrated ionic diameter of potassium, such as at least 5 %, at least 10%, at least 20%, at least 50% or more larger than the dehydrated ionic diameter of potassium.
  • the metal salt comprises one or more cations having a dehydrated ionic diameter that is smaller than the dehydrated ionic diameter of potassium, such as at least 5 %, at least 10%, at least 20%, at least 50% or more smaller than the dehydrated ionic diameter of potassium. In some embodiments, the metal salt comprises one or more cations having a dehydrated ionic diameter that is larger than, or smaller than, the dehydrated ionic diameter of potassium, such as at least 5 %, at least 10%, at least 20%, at least 50% or more larger or smaller than the dehydrated ionic diameter of potassium.
  • the metal salt comprises one or more cations having a hydrated ionic diameter that is larger than the hydrated ionic diameter of potassium, such as at least 5 %, at least 10%, at least 20%, at least 50% or more larger. In some embodiments, the metal salt comprises one or more cations having a hydrated ionic diameter that is smaller than the hydrated ionic diameter of potassium, such as at least 5 %, at least 10%, at least 20%, at least 50% or more smaller.
  • the metal salt comprises one or more cations having a hydrated ionic diameter that is larger than, or smaller than, the hydrated ionic diameter of potassium, such as at least 5 %, at least 10%, at least 20%, at least 50% or more larger or smaller than the hydrated ionic diameter of potassium.
  • the dehydrated and hydrated sizes of cations are known to the skilled person, for example, as provided in Kielland, J. "Individual activity coefficients of ions in aqueous solutions.” J. Am. Chem. Soc. 59:1675-1678, 1937.
  • a potassium cation may be the optimal size for forming and stabilising cation-mediated secondary structures, such as G-tetrads and G-quadruplexes; such that cations that are larger or smaller than potassium may reduce the formation of, and/or decrease the stability of, the cation-mediated secondary structures.
  • the metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 24- and Ca 2+ . In some embodiments, the metal salt comprises a cation selected from the group consisting of Na + , Cs + , Li + , Mg 2 * and Ca 2+ . In some embodiments, the metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + and Ca 2+ . In some embodiments, the metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + and Li + .
  • the metal salt comprises a Rb* cation, i.e. is a rubidium salt.
  • the metal salt comprises a Na + cation, i.e. is a sodium salt. Any suitable anion may be used in the metal salt.
  • Anions include fluoride, chloride, bromide, iodide, acetate, carbonate, citrate, phosphate, sulphite, sulphate, nitrite, nitrate, ferricyanide and ferrocyanide.
  • the one or more anions are selected from the group consisting of chloride, ferricyanide and ferrocyanide.
  • the anion may comprise chloride.
  • the anion may comprise ferricyanide and ferrocyanide.
  • the metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2 * and Ca 2+ as a ferricyanide salt and/or a ferrocyanide salt, typically as a mixture of a ferricyanide salt and ferrocyanide salt.
  • the metal salt comprise a cation selected from the group consisting of Na + , Cs + , Li + , Mg 2 * and Ca 2 * as a ferricyanide salt and/or a ferrocyanide salt, typically as a mixture of a ferricyanide salt and ferrocyanide salt.
  • the metal salt comprises one or more cations selected from the group consisting of Rb*, Na*, Cs*, Li* and Ca 2 * as a ferricyanide salt and/or a ferrocyanide salt, typically as a mixture of a ferricyanide salt and ferrocyanide salt.
  • the metal salt comprises one or more cations selected from the group consisting of Rb*, Na*, Cs* and Li* as a ferricyanide salt and/or a ferrocyanide salt, typically as a mixture of a ferricyanide salt and ferrocyanide salt.
  • the metal salt comprises rubidium ferricyanide and/or rubidium ferrocyanide, typically a mixture of rubidium ferricyanide and rubidium ferrocyanide.
  • the metal salt is sodium ferricyanide and/or sodium ferrocyanide, typically a mixture of sodium ferricyanide and sodium ferrocyanide.
  • the metal salt comprises one or more cations selected from the group consisting of Rb*, Na*, Cs*, Li*, Mg 2 * and Ca 2 * as a chloride salt. In some embodiments, the metal salt comprise one or more cation selected from the group consisting of Na*, Cs*, Li*, Mg 2 * and Ca 2 * as a chloride salt. In some embodiments, the metal salt comprises one or more cations selected from the group consisting of Rb*, Na*, Cs*, Li* and Ca 2 * as a chloride salt. In some embodiments, the metal salt comprises one or more cations selected from the group consisting of Rb*, Na*, Cs* and Li* as a chloride salt.
  • the metal salt comprises rubidium chloride. In some embodiments, the metal salt comprises sodium chloride.
  • the metal salt may comprise a mixture of anions described above, such as a mixture of ferricyanide, ferrocyanide and chloride anions.
  • the metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2 * and Ca 2+ , and one or more anions comprising (i) chloride and (ii) ferricyanide and/or ferrocyanide, typically a mixture of ferricyanide and ferrocyanide.
  • the metal salt comprises one or more cations selected from the group consisting of Na + , Cs + , Li + , Mg 2 * and Ca 2 *, and one or more anions comprising (i) chloride and (ii) ferricyanide and/or ferrocyanide, typically a mixture of ferricyanide and ferrocyanide.
  • the metal salt comprises one or more cations selected from the group consisting of Rb*, Na* Cs* Li* and Ca 2 *, and one or more anions comprising (i) chloride and (ii) ferricyanide and/or ferrocyanide, typically a mixture of ferricyanide and ferrocyanide.
  • the metal salt comprises one or more cations selected from the group consisting of Rb*, Na*, Cs* and Li*, and one or more anions comprising (i) chloride and (ii) ferricyanide and/or ferrocyanide, typically a mixture of ferricyanide and ferrocyanide.
  • the metal salt comprises (i) rubidium chloride and (ii) rubidium ferricyanide and/or rubidium ferrocyanide, typically a mixture of rubidium ferricyanide and rubidium ferrocyanide.
  • the metal salt comprises (i) sodium chloride and (ii) sodium ferricyanide and/or sodium ferrocyanide, typically a mixture of sodium ferricyanide and sodium ferrocyanide.
  • the beneficial effects identified by the inventors when the metal salt comprises a cation selected from the group consisting of Rb*, Na*, Cs*, Li*, Mg 2 * and Ca 2 * are a feature of the present disclosure.
  • the signalmoise ratio of measurements taken in a nanopore system as a polynucleotide moves with respect to a nanopore may correlate with base-calling accuracy.
  • Conditions which decrease formation of cation-mediated secondary structure are conventionally associated with a decreased signalmoise ratio compared to corresponding conditions comprising potassium salts.
  • the inventors have surprisingly found that base-calling accuracy of nanopore measurements may be retained even under conditions which decrease formation of cation-mediated secondary structure.
  • the concentration of the metal salt is from about 0.01 to about 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M. In some embodiments, the concentration of the metal salt is about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M. Where the metal salt is a mixture of two or more salts, the total concentration of the metal salts in the mixture is from 0.01 to 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M.
  • the total concentration of the metal salt is about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M.
  • the concentration of the metal salts in the mixture are identical.
  • the concentration of the metal salts in the mixture are not identical.
  • the concentration of the metal salts may comprise a ratio of 1 : 1.5, 1 :2, 1:2.5, 1:3, 1:3.5, 1:4 or 1:5.
  • the metal salt comprises a Na + cation and the concentration of the metal salt is from 0.01 to 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M, such as about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M.
  • the metal salt comprises a Rb + cation and the concentration of the metal salt is from 0.01 to 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M, such as about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M.
  • the metal salt comprises a mixture of a ferricyanide salt and ferrocyanide salt, and the total concentration of the metal salts in the mixture is from 0.01 to 1 M, typically from 0.02 to 0.5 M or from 0.05 to 0.3 M, such as about 0.025 M, about 0.05 M, about 0.075 M, about 0.1 M, about 0.15 M, about 0.2 M, about 0.25 M or about 0.3 M.
  • the metal salt comprises about 0.01 to about 1 M rubidium ferricyanide, typically from 0.02 to 0.5 M, from 0.05 to 0.3 M, from 0.1 to 0.2 M, or about 0.15 M rubidium ferricyanide.
  • the metal salt comprises about 0.01 to about 1 M rubidium ferrocyanide, typically from 0.02 to 0.5 M, from 0.05 to 0.3 M, from 0.1 to 0.2 M, or about 0.15 M rubidium ferrocyanide. In some embodiments, the metal salt comprises about 0.005 to about 0.1 M rubidium phosphate, typically from 0.01 to 0.05 M, from 0.02 to 0. 03 M, or about 0.025 M rubidium phosphate.
  • the metal salt comprises about 0.01 to about 1 M rubidium ferricyanide, 0.01 to about 1 M rubidium ferrocyanide and about 0.005 to about 0.1 M rubidium phosphate, typically: from 0.02 to 0.5 M rubidium ferricyanide, from 0.02 to 0.5 M rubidium ferrocyanide and 0.005 to 0.01 M rubidium phosphate; from 0.05 to 0.3 M rubidium ferricyanide, from 0.05 to 0.3 M rubidium ferrocyanide and 0.01 to 0.05 M rubidium phosphate; from 0.1 to 0.2 M rubidium ferricyanide, from 0.1 to 0.2 M rubidium ferrocyanide and 0.02 to 0.03 M rubidium phosphate; or about 0.15 M rubidium ferricyanide, about 0.15 M rubidium ferrocyanide and about 0.025 M rubidium phosphate.
  • the metal salt comprises about 0.01 to about 1 M sodium ferricyanide, typically from 0.02 to 0.5 M, from 0.05 to 0.3 M, from 0.1 to 0.2 M, or about 0.15 M or about 0.21 M sodium ferricyanide. In some embodiments, the metal salt comprises about 0.01 to about 1 M sodium ferrocyanide, typically from 0.02 to 0.5 M, from 0.05 to 0.3 M, from 0.1 to 0.2 M, or about 0.15 M or about 0.21 M sodium ferrocyanide. In some embodiments, the metal salt comprises about 0.005 to about 0.1 M sodium phosphate, typically from 0.01 to 0.05 M, from 0.02 to 0. 03 M, or about 0.025 M sodium phosphate.
  • the metal salt comprises about 0.01 to about 1 M sodium ferricyanide, 0.01 to about 1 M sodium ferrocyanide and about 0.005 to about 0.1 M sodium phosphate, typically: from 0.02 to 0.5 M sodium ferricyanide, from 0.02 to 0.5 M sodium ferrocyanide and 0.005 to 0.01 M sodium phosphate; from 0.05 to 0.3 M sodium ferricyanide, from 0.05 to 0.3 M sodium ferrocyanide and 0.01 to 0.05 M sodium phosphate; from 0.1 to 0.2 M sodium ferricyanide, from 0.1 to 0.2 M sodium ferrocyanide and 0.02 to 0.03 M sodium phosphate; about 0.15 M sodium ferricyanide, about 0.15 M sodium ferrocyanide and about 0.025 M sodium phosphate; or about 0.21 M sodium ferricyanide, about 0.21 M sodium ferrocyanide and about 0.025 M sodium phosphate.
  • the conditions comprise a further metal salt as a charge carrier.
  • the additional metal salt is not a potassium salt.
  • the further metal salt comprises one or more monovalent or divalent metal salts.
  • the further metal salt comprises one or more monovalent metal salts.
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2+ and Ca 2+ , typically Rb + or Na + .
  • the further metal salt comprises a cation selected from the group consisting of Na + , Cs + , Li + , Mg 2+ and Ca 2+ , typically Na +
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + and Ca 2+ .
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + and Li + .
  • the further metal salt is a chloride salt.
  • the further metal salt comprises one or more chloride salts comprising a cation selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2+ and Ca 2+ , typically Rb + or Na + .
  • the further metal salt is a chloride salt comprising a cation selected from the group consisting of Na + , Cs + , Li + , Mg 2+ and Ca 2+ , typically Na + .
  • the further metal salt comprises one or more chloride salts comprising a cation selected from the group consisting of Rb + , Na + , Cs + , Li + , and Ca 2+ .
  • the further metal salt comprises one or more chloride salts comprising a cation selected from the group consisting of Rb + , Na + , Cs + and Li + .
  • the further metal salt comprises RbCl.
  • the further metal salt is NaCl.
  • the concentration of the further metal salt is at saturation.
  • the concentration of the further metal salt is 3 M or lower, typically from 0.1 to 2.5 M, from 0.3 to 1.9 M, from 0.5 to 1.8 M, from 0.7 to 1.7 M, from 0.9 to 1.6 M or from 1 M to 1.4 M.
  • the concentration of the further metal salt is preferably from 150 mM to 1 M.
  • the method is preferably carried out using a salt concentration of at least 0.3 M, such as at least 0.4 M, at least 0.5 M, at least 0.6 M, at least 0.8 M, at least 1.0 M, at least 1.5 M, at least 2.0 M, at least 2.5 M or at least 3.0 M.
  • a salt concentration of at least 0.3 M such as at least 0.4 M, at least 0.5 M, at least 0.6 M, at least 0.8 M, at least 1.0 M, at least 1.5 M, at least 2.0 M, at least 2.5 M or at least 3.0 M.
  • High concentrations of the further metal salt provide a high signal to noise ratio and allow for currents indicative of the presence of a nucleotide to be identified against the background of normal current fluctuations.
  • the decrease of cation-mediated secondary structure formation is typically compared to a reference condition.
  • the reference condition comprises a potassium salt.
  • the method is conducted under conditions comprising 500 mM or less of potassium salt, such as 100 mM potassium salt or less, 10 mM potassium salt or less, 1 mM potassium salt or less, 1 pM potassium salt or less, or 100 nM potassium salt or less.
  • 50% or less, such as 10% or less, e.g. 1 % or less of the salt in the conditions is a potassium salt, such as 0.1% or less, 0.01% or less, or 0.001% or less.
  • the conditions are substantially free of a potassium salt.
  • a condition is substantially free of potassium salt when potassium cation-mediated secondary structure is absent or undetectable by the use of standard biochemical techniques.
  • the one or more conditions which decrease formation of cation-mediated secondary structure are contacted with the portion of the polynucleotide that has translocated through the nanopore.
  • the one or more conditions on each side of the membrane are symmetric, i.e. the one or more conditions are the same on the cis and the trans sides of the membrane.
  • the one or more conditions on each side of the membrane comprise a salt as described herein, such as a salt comprising an ammonium cation (NH4 + ) and/or a metal salt.
  • the one or more conditions on each side of the membrane comprise a metal salt as described herein.
  • the one or more conditions on each side of the membrane may comprise one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2+ and Ca 2+ . In some embodiments, the one or more conditions on each side of the membrane may comprise one or more cations selected from the group consisting of Na + , Cs + , Li + , Mg 2+ and Ca 2+ . In some embodiments, the one or more conditions on each side of the membrane may comprise one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + and Ca 2+ .
  • the one or more conditions on each side of the membrane may comprise one or more cations selected from the group consisting of Rb + , Na + , Cs + and Li + .
  • the one or more conditions on each side of the membrane may comprise a Rb + catibn.
  • the one or more conditions on each side of the membrane may comprise a Na + cation.
  • the one or more conditions on the trans side of the membrane may comprise a salt as described herein, such as a salt comprising an ammonium cation (NHZ) and/or a metal salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2+ and Ca 2+ .
  • the conditions on the cis side of the membrane may or may not comprise one or more conditions decrease formation of cation-mediated secondary structure.
  • the one or more conditions on the cis side of the membrane may comprise a salt as described herein, such as a salt comprising an ammonium cation (NHZ) and/or a metal salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 24- and Ca 2+ .
  • the conditions on the trans side of the membrane may or may not comprise one or more conditions decrease formation of cation-mediated secondary structure.
  • the methods comprise translocating a portion of a polynucleotide through a nanopore in a first direction with respect to the nanopore, wherein the first direction is from the first opening to the second opening, and translocating the polynucleotide in a second direction with respect to the nanopore, wherein the second direction is from the second opening to the first opening.
  • the nanopore is in a membrane having a cis side and a trans side, the first opening of the nanopore is at the cis side of the membrane and the second opening of the nanopore is at the trans side, and a portion of the polynucleotide translocates though the nanopore in a first direction from the cis side to the trans side of the membrane.
  • the nanopore is in a membrane having a cis side and a trans side, the first opening of the nanopore is at the trans side of the membrane and the second opening of the nanopore is at the cis side, and a portion of the polynucleotide translocates though the nanopore in a first direction from the trans side to the cis side of the membrane.
  • a portion of the polynucleotide is typically sufficient in length to form a cation- mediated secondary structure.
  • the portion of the polynucleotide is 15 nucleotides in length or more, such as 25 nucleotides in length or more, 50 nucleotides in length or more, 100 nucleotides in length or more, 500 nucleotides in length or more, 1000 nucleotides in length or more, 5000 nucleotides in length or more, 10000 nucleotides in length or more, 50000 nucleotides in length or more, or 100000 nucleotides in length or more.
  • the portion of the polynucleotide is at least 1% of the total length of the polynucleotide, such as at least 5% of the total length of the polynucleotide, at least 10% of the total length of the polynucleotide, at least 20% of the total length of the polynucleotide, at least 30% of the total length of the polynucleotide, at least 40% of the total length of the polynucleotide, at least 50% of the total length of the polynucleotide, at least 60% of the total length of the polynucleotide, at least 70% of the total length of the polynucleotide, at least 80% of the total length of the polynucleotide, of the total length of the polynucleotide, at least 90% of the total length of the polynucleotide, or at least 95% of the total length of the polynucleotide.
  • the portion is the full length of the polynucleotide, i.e. the entire polynucleotide is translocated through the nanopore.
  • the term “translocating” relates to the movement of a polynucleotide in the first direction or the second direction with respect to the nanopore, i.e. does not necessarily require that the full polynucleotide passes through the nanopore and is subsequently released.
  • the portion of the polynucleotide comprises a sequence that is capable of forming a cation-mediated secondary structure as described herein (such as a G quadruplex) under reference conditions.
  • the reference condition comprises a potassium salt, as discussed herein.
  • the methods comprise controlling the movement of the polynucleotide, or of each polynucleotide, with respect to the nanopore in the first direction using a polynucleotide-handling protein. In some embodiments, the methods comprises controlling the movement of the polynucleotide, or of each polynucleotide, with respect to the nanopore in the second direction using a polynucleotide-handling protein.
  • the methods comprise controlling the movement of the polynucleotide, or of each polynucleotide, with respect to the nanopore in the first direction using a polynucleotide-handling protein and controlling the movement of the polynucleotide, or of each polynucleotide, with respect to the nanopore in the second direction using a polynucleotide-handling protein.
  • the presence, absence or one or more characteristics of the target polynucleotide are determined.
  • the methods are for determining the presence, absence or one or more characteristics of a polynucleotide.
  • the methods concern determining the presence, absence or one or more characteristics of two or more polynucleotides.
  • the methods may comprise determining the presence, absence or one or more characteristics of any number of polynucleotides, such as 2, 5, 10, 15, 20, 30, 40, 50, 100 or more polynucleotides. Any number of characteristics of the one or more target polynucleotides may be determined, such as 1, 2, 3, 4, 5, 10 or more characteristics.
  • Characteristics amenable to being detected in the methods include (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide and (v) whether or not the polynucleotide is modified.
  • the methods provided herein are methods of sequencing a target polynucleotide.
  • a polynucleotide sequence may be determined in real-time by aligning real-time signal or basecalling to known references.
  • the methods comprise determining if a measured characteristic of the polynucleotide is indicative of one or more desired or undesired characteristics of the polynucleotides.
  • the methods comprise determining the presence or absence of one or more desired characteristic. In some embodiments, if the measurements characteristic of the polynucleotide are indicative of a desired characteristic, the method comprises fully translocating the polynucleotide in the first direction. In some embodiments, if the measurements characteristic of the polynucleotide are indicative of a desired characteristic, the method comprises repeating the translocation of the polynucleotide in the first and the second directions multiple times. This allows re-reading approaches as described in WO 2021/255476, incorporated herein by reference, to be applied to the disclosed methods, as described above.
  • the desired characteristic may be the ability of the polynucleotide to translocate through the pore.
  • the desired characteristic may be the sequence of a polynucleotide of interest, for example a particular genomic region.
  • the methods comprise determining the presence or absence of one or more undesired characteristic. In some embodiments, if the measurements characteristic of the polynucleotide are indicative of an undesired characteristic, the method comprises ejecting the polynucleotide from the first opening of the nanopore. In some embodiments, ejecting the polynucleotide comprises translocating the portion of the polynucleotide through the nanopore in the second direction. In some embodiments, the one or more undesired characteristic includes the inability of the polynucleotide to fully translocate through the nanopore in the first direction with respect to the nanopore, i.e. the polynucleotide blocks the pore.
  • a method of characterising a polynucleotide comprises translocating a portion of the polynucleotide through the nanopore in the first direction with respect to the nanopore, determining the presence or absence of the inability of the polynucleotide to fully translocate through the nanopore in the first direction, wherein if the polynucleotide is unable to fully translocate through the nanopore in the first direction with respect to the nanopore, the method further comprises ejecting the polynucleotide from the first opening of the nanopore translocating the portion of the polynucleotide through the nanopore in the second direction.
  • the one or more undesired characteristic is the sequence of a polynucleotide that is not of interest.
  • the method may comprise ejecting the polynucleotide with the undesired characteristic from the first opening of the nanopore.
  • the methods comprise:
  • the nanopore is in a membrane having a cis side and a trans side, the first opening of the nanopore is at the cis side of the membrane and the second opening of the nanopore is at the trans side, a portion of the polynucleotide translocates though the nanopore in a first direction from the cis side to the trans side of the membrane; the translocated portion of the polynucleotide is contacted with one or more conditions which decrease formation of cation-mediated secondary structure; and the polynucleotide is translocated in a second direction from the trans side to the cis side of the membrane; and the method further comprises taking one or more measurements characteristic of the polynucleotide during the translocation of the polynucleotide through the nanopore.
  • the method comprises translocating the entire polynucleotide through the nanopore in the first direction from the cis side to the trans side of the membrane, and taking one or more measurements during said translocation; whereas if the measurements characteristic of the polynucleotide are indicative of one or more undesired characteristics of the polynucleotide, the method comprises ejecting the polynucleotide from the first opening of the nanopore by translocating the portion of the polynucleotide in the second direction from the trans side to the cis side of the membrane.
  • the nanopore is in a membrane having a cis side and a trans side, the first opening of the nanopore is at the trans side of the membrane and the second opening of the nanopore is at the cis side, a portion of the polynucleotide translocates though the nanopore in a first direction from the trans side to the cis side of the membrane; the translocated portion of the polynucleotide is contacted with one or more conditions which decrease formation of cation-mediated secondary structure; and the polynucleotide is translocated in a second direction from the cis side to the trans side of the membrane; and the method further comprises taking one or more measurements characteristic of the polynucleotide during the translocation of the polynucleotide through the nanopore.
  • the method comprises translocating the entire polynucleotide through the nanopore in the first direction from the trans side to the cis side of the membrane, and taking one or more measurements during said translocation; whereas if the measurements characteristic of the polynucleotide are indicative of one or more undesired characteristics of the polynucleotide, the method comprises ejecting the polynucleotide from the first opening of the nanopore by translocating the portion of the polynucleotide in the second direction from the cis side to the trans side of the membrane. Ejecting a polynucleotide
  • the methods comprise ejecting a polynucleotide, particularly is the polynucleotide comprises measured characteristics that are indicative of one or more undesired characteristic or the lack of a desired characteristic.
  • the polynucleotide is ejected from the first opening of the nanopore. Accordingly, to eject the polynucleotide, the polynucleotide is translocated in the second direction with respect to the nanopore. The full polynucleotide is translocated through the nanopore in the second direction such that a further polynucleotide may be contacted with the pore and translocated in the first direction and/or in the second direction.
  • the polynucleotide is ejected from the nanopore by applying a force across the nanopore which causes the polynucleotide to move in the second direction, i.e. in the direction from the second opening of the nanopore to the first opening of the nanopore.
  • the force is a voltage force.
  • the ejection force is opposite in direction to a voltage force applied across the membrane during the translocation of the polynucleotide in the first direction, i.e. from the first opening of the nanopore to the second opening of the nanopore.
  • the translocation in the first direction is carried out under a positive voltage and the ejection voltage is a negative voltage.
  • the voltage is applied at the trans side of the nanopore relative to the cis side of the nanopore.
  • the translocation in the first direction is carried out under a negative voltage and the ejection voltage is a positive voltage.
  • the voltage is applied at the cis side of the nanopore relative to the trans side of the nanopore.
  • the methods disclosed herein involve characterising a polynucleotide.
  • a polynucleotide such as a nucleic acid, is a macromolecule comprising two or more nucleotides.
  • a polynucleotide can be single-stranded or double-stranded.
  • a doublestranded polynucleotide is made of two single stranded polynucleotides hybridised ’together.
  • the polynucleotide can be a single-stranded polynucleotide or a double-stranded polynucleotide as described in more detail herein.
  • the portion of the polynucleotide that translocates through the pore in the first direction is typically a single-stranded portion of the polynucleotide.
  • a polynucleotide may comprise any combination of any nucleotides.
  • the nucleotides can be naturally occurring or artificial.
  • a nucleotide typically contains a nucleobase, a sugar and at least one phosphate group.
  • the nucleobase and sugar form a nucleoside.
  • the nucleobase is typically heterocyclic. Nucleobases include, but are not limited to, purines and pyrimidines and more specifically adenine (A), guanine (G), thymine (T), uracil (U) and cytosine (C).
  • A adenine
  • G guanine
  • T thymine
  • U uracil
  • C cytosine
  • the sugar is typically a pentose sugar.
  • Nucleotide sugars include, but are not limited to, ribose and deoxyribose.
  • the sugar is preferably a deoxyribose.
  • the polynucleotide preferably comprises the following nucleosides: deoxyadenosine (dA), deoxyuridine (dU) and/or thymidine (dT), deoxyguanosine (dG) and deoxycytidine (dC).
  • the nucleotide is typically a ribonucleotide or deoxyribonucleotide.
  • the nucleotide typically contains a monophosphate, diphosphate or triphosphate.
  • the nucleotide may comprise more than three phosphates, such as 4 or 5 phosphates. Phosphates may be attached on the 5’ or 3’ side of a nucleotide.
  • Nucleotides include, but are not limited to, adenosine monophosphate (AMP), guanosine monophosphate (GMP), thymidine monophosphate (TMP), uridine monophosphate (UMP), 5-methylcytidine monophosphate, 5 -hydroxymethylcytidine monophosphate, cytidine monophosphate (CMP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), deoxyadenosine monophosphate (dAMP), deoxyguanosine monophosphate (dGMP), deoxythymidine monophosphate (dTMP), deoxyuridine monophosphate (dUMP), deoxycytidine monophosphate (dCMP) and deoxymethylcytidine monophosphate.
  • the nucleotides are preferably selected from AMP, TMP, GMP, CMP, UMP, dAMP, dTMP, dGMP, dCMP and dUMP
  • a nucleotide may be abasic (i.e. lack a nucleobase).
  • a nucleotide may also lack a nucleobase and a sugar (i.e. is a C3 spacer).
  • the polynucleotide can be any length. In some embodiments, the polynucleotide is at least 100, at least 150, at least 200, at least 250, at least 300, at least 400 or at least 500 nucleotides or nucleotide pairs in length.
  • the polynucleotide can be 1000 or more nucleotides or nucleotide pairs in length, 5000 or more nucleotides or nucleotide pairs in length or 100000 or more nucleotides or nucleotide pairs in length or 500,000 or more nucleotides or nucleotide pairs in length, or 1,000,000 or more nucleotides or nucleotide pairs in length, 10,000,000 or more nucleotides or nucleotide pairs in length, or 100,000,000 or more nucleotides or nucleotide pairs in length, or 200,000,000 or more nucleotides or nucleotide pairs in length, or the entire length of a chromosome.
  • polynucleotides such as those at least 500 nucleotides or nucleotide pairs in length have particular use in the methods disclosed herein, as the chance of encountering a sequence that may form a cation-mediated secondary structure increases and thus the advantages of the methods are most easily recognisable.
  • the method disclosed herein involves a plurality of polynucleotides
  • the plurality of polynucleotides may have an average (e.g.
  • the methods disclosed herein are of particular use for characterising polynucleotides of a longer average (e.g. median) length, such as those at least 5,000 nucleotides or nucleotide pairs in length, particularly wherein the plurality of polynucleotides are derived from a genomic sample, and the frequency of occurrence of cation-mediated secondary structure is unknown.
  • the polynucleotide may be a fragment of a longer polynucleotide.
  • the longer polynucleotide is typically fragmented into multiple, such as two or more, shorter polynucleotides.
  • the polynucleotide comprises a sequence that is capable of forming cation-mediated secondary structure, such as a G-tetrad and/or a G-quadruplex. In some embodiments, the polynucleotide comprises a sequence that is rich in guanosine nucleotides which is capable of forming cation-mediated secondary structure, such as a G- tetrad and/or a G-quadruplex. Typically, a sequence rich in guanosine nucleotides is 15 nucleotides in length or more and comprises 50% or more guanine bases.
  • the nucleotides in the polynucleotide may be attached to each other in any manner.
  • the nucleotides are typically attached by their sugar and phosphate groups as in nucleic acids.
  • the nucleotides may be connected via their nucleobases as in pyrimidine dimers.
  • the polynucleotide can be a nucleic acid, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
  • the polynucleotide can comprise one strand of RNA hybridized to one strand of DNA.
  • the polynucleotide may be any synthetic nucleic acid known in the art, such as peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), locked nucleic acid (LNA), bridged nucleic acid (BNA) or other synthetic polymers with nucleotide side chains.
  • PNA peptide nucleic acid
  • GNA glycerol nucleic acid
  • TAA threose nucleic acid
  • LNA locked nucleic acid
  • BNA bridged nucleic acid
  • the PNA backbone is composed of repeating N-(2- aminoethyl)-glycine units linked by peptide bonds
  • the GNA backbone is composed of repeating glycol units linked by phosphodiester bonds.
  • the TNA backbone is composed of repeating threose sugars linked together by phosphodiester bonds.
  • LNA is formed from ribonucleotides as discussed above having an extra bridge connecting the 2' oxygen and 4' carbon in the ribose moiety.
  • the polynucleotide is typically DNA, RNA or a DNA or RNA hybrid, most preferably DNA.
  • a DNA/RNA hybrid may comprise DNA and RNA on the same strand.
  • the DNA/RNA hybrid comprises one DNA strand hybridized to an RNA strand.
  • the backbone of the polynucleotide can be altered to reduce the possibility of strand scission.
  • DNA is known to be more stable than RNA under many conditions.
  • the backbone of the polynucleotide strand can be modified to avoid damage caused by e.g. harsh chemicals such as free radicals.
  • DNA or RNA that contains unnatural or modified bases can be produced by amplifying natural DNA or RNA polynucleotides in the presence of modified NTPs using an appropriate polymerase.
  • the nucleotides in the polynucleotide may be modified.
  • the nucleotides may be oxidized or methylated.
  • One or more nucleotides in the polynucleotide may be damaged.
  • the polynucleotide may comprise a pyrimidine dimer. Such dimers are typically associated with damage by ultraviolet light and are the primary cause of skin melanomas.
  • One or more nucleotides in the polynucleotide may be modified with a label or a tag.
  • the polynucleotide is a double-stranded polynucleotide. In some embodiments, prior to contacting the polynucleotide with a nanopore, the polynucleotide is comprised in or consists of a first strand of a double-stranded polynucleotide comprising said first strand and a second strand.
  • the polynucleotide is a double-stranded polynucleotide and the first strand is hybridised to the second strand.
  • the two strands of a double-stranded molecule are attached together.
  • the first strand may be attached to the second strand.
  • the two strands may be covalently linked, for example at the ends of the molecules by joining the 5’ end of one strand to the 3’ end of the other with a hairpin structure.
  • the polynucleotide may comprise the products of a PCR reaction, genomic DNA, the products of an endonuclease digestion and/or a DNA library.
  • the polynucleotide may be naturally occurring.
  • the polynucleotide may be secreted from cells.
  • the polynucleotide may be present inside cells such that the polynucleotide must be extracted from the cells before the method can be carried out.
  • the polynucleotide may be sourced from common organisms such as viruses, bacteria, archaea, plants or animals. Such organisms may be selected or altered to adjust the sequence of the target polynucleotide, for example by adjusting the base composition, removing unwanted sequence elements, and the like. The selection and alteration of organisms in order to arrive at desired polynucleotide characteristics is routine for one of ordinary skill in the art.
  • the source organism for the polynucleotide may be chosen based on desired characteristics of the sequence. Desired characteristics include the ratio of single-stranded vs double-stranded polynucleotides produced by the organism; the complexity of the sequences of polynucleotides produced by the organism, the composition of the polynucleotides produced by the organism (such as the GC composition), or the length of contiguous polynucleotide strands produced by the organism. For example, when a contiguous polynucleotide strand of around 50 kb is required, lambda phage DNA can be used. If longer contiguous strands are required, other organisms can be used to produce the polynucleotide; for example E. coli produces around 4.5 Mb of contiguous dsDNA.
  • the polynucleotide is typically obtained from a human or animal, e.g. from urine, lymph, saliva, mucus, seminal fluid or amniotic fluid, or from whole blood, plasma or serum.
  • the polynucleotide may be obtained from a plant e.g. a cereal, legume, fruit or vegetable.
  • the polynucleotide may comprise genomic DNA.
  • the genomic DNA may be fragmented.
  • the DNA may be fragmented by any suitable method. For example, methods of fragmenting DNA are known in the art. Such methods may use a transposase, such as a MuA transposase. Often the genomic DNA is not fragmented.
  • the polynucleotide is synthetic or semi-synthetic.
  • DNA or RNA may be purely synthetic, synthesised by conventional DNA synthesis methods such as phosphoramidite based chemistries.
  • Synthetic polynucleotides subunits may be joined together by known means, such as ligation or chemical linkage, to produce longer strands.
  • internal self-forming structures e.g. hairpins, quadruplexes
  • Synthetic polynucleotides can be copied and scaled up for production by means known in the art, including PCR, incorporation into bacterial factories, and the like.
  • the polynucleotide may have a simplified nucleotide composition.
  • the polynucleotide has a repeating pattern of the same subunit.
  • a repeating unit may be (AmGn)q, wherein m, n and q are positive integers.
  • m is often from 1 to 20, such as from 1 to 10 e.g. from 1 to 5, e.g. 1, 2, 3, 4 or 5.
  • n is often from 1 to 20, such as from 1 to 10 e.g. from 1 to 5, e.g. 1, 2, 3, 4 or 5.
  • m and n may be the same or different, q is often from 1 to about 100,000.
  • a typical repeating unit may be for example (AAAAAAGGGGGG)q.
  • Repeating polynucleotides can be made by many means known in the art, for example by concatenating together synthetic subunits with sticky ends that enable ligation.
  • the polynucleotide may therefore be a concatenated polynucleotide. Methods of concatenating polynucleotides are described in PCT/GB2017/051493.
  • any number of polynucleotides can be used in the disclosed methods.
  • the method may comprise using 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 100 or more polynucleotides.
  • the disclosed methods reduce the chances of pore blocking by a polynucleotide by enabling the polynucleotide blocking the nanopore to be ejected, thus allowing additional polynucleotides to be used.
  • two or more polynucleotides are used, they may be different polynucleotides or two instances of the same polynucleotide.
  • the polynucleotide can be naturally occurring or artificial.
  • the polynucleotide is labelled with a molecular label.
  • a molecular label may be a modification to the polynucleotide which promotes the detection of the polynucleotide in the methods provided herein.
  • the label may interfere with a flux of ions through the nanopore. In such a manner, the label may improve the sensitivity of the methods.
  • a polynucleotide may have a polynucleotide adapter attached thereto.
  • An adapter typically comprises a polynucleotide strand capable of being attached to the end of the polynucleotide.
  • the methods comprise attaching an adapter (e.g. an adapter as described herein) to a polynucleotide.
  • the adapter is synthetic or artificial.
  • the adapter comprises a polymer as described herein.
  • the adapter comprises a spacer as described herein.
  • the adapter comprises a polynucleotide.
  • the polynucleotide adapter may comprise DNA, RNA, modified DNA (such as abasic DNA), RNA, PNA, LNA, BNA and/or PEG.
  • the adapter comprises single stranded and/or double stranded DNA or RNA.
  • the adapter may comprise the same type of polynucleotide as the polynucleotide strand to which it is attached.
  • the adapter may comprise a different type of polynucleotide to the polynucleotide strand to which it is attached.
  • the polynucleotide used in the disclosed methods is a single stranded DNA strand and the adapter comprises DNA or RNA, typically single stranded DNA.
  • the polynucleotide is a double stranded DNA strand and the adapter comprises DNA or RNA, e.g. double or single stranded DNA.
  • an adapter may be a bridging moiety.
  • a bridging moiety may be used to connect the two strands of a double-stranded polynucleotide.
  • a bridging moiety is used to connect the template strand of a double stranded polynucleotide to the complement strand of the double stranded polynucleotide.
  • a bridging moiety typically covalently links the two strands of a double-stranded polynucleotide.
  • the bridging moiety can be anything that is capable of linking the two strands of a double-stranded polynucleotide, provided that the bridging moiety does not interfere with movement of the polynucleotide with respect to the nanopore.
  • Suitable bridging moieties include, but are not limited to a polymeric linker, a chemical linker, a polynucleotide or a polypeptide.
  • the bridging moiety comprises DNA, RNA, modified DNA (such as abasic DNA), RNA, PNA, LNA or PEG.
  • the bridging moiety is more preferably DNA or RNA.
  • a bridging moiety is a hairpin adapter.
  • a hairpin adapter is an adapter comprising a single polynucleotide strand, wherein the ends of the polynucleotide strand are capable of hybridising to each other, or are hybridized to each other, and wherein the middle section of the polynucleotide forms a loop.
  • Suitable hairpin adapters can be designed using methods known in the art.
  • a hairpin loop is typically 4 to 100 nucleotides in length, e.g. from 4 to 50 such as from 4 to 20 e.g. from 4 to 8 nucleotides in length.
  • the bridging moiety e.g.
  • hairpin adapter is attached at one end of a double-stranded polynucleotide.
  • a bridging moiety e.g. hairpin adapter
  • hairpin adapter is typically not attached at both ends of a double-stranded polynucleotide.
  • a polynucleotide may have a sequencing adapter attached thereto.
  • a sequencing adapter is typically loaded with a polynucleotide-handling protein, such as a motor protein.
  • the polynucleotide-handling protein may be stalled at a spacer on the sequencing adapter. Examples of suitable sequencing adapters are disclosed in WO 2015/110813 and WO 2020/234612, which are herein incorporated by reference.
  • an adapter is a linear adapter.
  • a linear adapter may be bound to either or both ends of a single stranded polynucleotide.
  • a linear adapter may be bound to either or both ends of either or both strands of the double stranded polynucleotide.
  • a linear adapter may comprise a leader sequence as described herein.
  • a linear adapter may comprise a portion for hybridisation with a tag (such as a pore tag) as described herein.
  • a linear adapter may be 10 to 150 nucleotides in length, such as from 20 to 120, e.g. 30 to 100, for example 40 to 80 such as 50 to 70 nucleotides in length.
  • a linear adapter may be single stranded.
  • a linear adapter may be double stranded.
  • an adapter may be a Y adapter.
  • a Y adapter is typically a polynucleotide adapter.
  • a Y adapter is typically double stranded and comprises (a) at one end, a region where the two strands are hybridised together and (b), at the other end, a region where the two strands are not complementary.
  • the non-complementary parts of the strands typically form overhangs.
  • the presence of a non-complementary region in the Y adapter gives the adapter its Y shape since the two strands typically do not hybridise to each other unlike the double stranded portion.
  • the two single-stranded portions of the Y adapter may be the same length, or may be different lengths.
  • one singlestranded portion of the Y adapter may be 10 to 150 nucleotides in length, such as from 20 to 120, e.g. 30 to 100, for example 40 to 80 such as 50 to 70 nucleotides in length and the other single stranded portion of the Y adapter may independently by 10 to 150 nucleotides in length, such as from 20 to 120, e.g. 30 to 100, for example 40 to 80 such as 50 to 70 nucleotides in length.
  • the double-stranded “stem” portion of the Y adapter may be e.g. from 10 to 150 nucleotides in length, such as from 20 to 120, e.g. 30 to 100, for example 40 to 80 such as 50 to 70 nucleotides in length.
  • a Y adapter may be attached to either or both ends of the construct described herein.
  • An adapter may be linked to a polynucleotide by any suitable means known in the art.
  • the adapter may be synthesized separately and chemically attached or enzymatically ligated to the polynucleotide. Alternatively, the adapter may be generated in the processing of the polynucleotide.
  • the adapter is linked to the polynucleotide at or near one end of the target polynucleotide. In some embodiments, the adapter is linked to the polynucleotide within 50, e.g. within 20 for example within 10 nucleotides of an end of the polynucleotide.
  • the adapter is linked to the polynucleotide at a terminus of the polynucleotide.
  • the adapter may comprise the same type of nucleotides as the polynucleotide or may comprise different nucleotides to the polynucleotide.
  • a polynucleotide or an adapter as described herein may comprise a spacer.
  • one or more spacers may be present in a polynucleotide adapter.
  • a polynucleotide or polynucleotide adapter may comprise one or more spacers, e.g. from one to about 10 spacers, e.g. from 1 to about 5 spacers, e.g. 1, 2, 3, 4 or 5 spacers.
  • the spacer may comprise any suitable number of spacer units.
  • a spacer typically provides an energy barrier which impedes movement of a polynucleotide binding protein.
  • a spacer may impede movement of a polynucleotide- handling protein by reducing the traction of the protein, e.g. using an abasic spacer.
  • a spacer may physically block movement of the protein, for instance by introducing a bulky chemical group to physically impede the movement of the polynucleotide-handling protein.
  • one or more spacers are included in the polynucleotide or in a polynucleotide adapter to provide a distinctive signal when they pass through or across a nanopore.
  • One or more spacers may be used to define or separate one or more regions of a polynucleotide; e.g. to separate an adapter from the target polynucleotide.
  • a spacer may comprise a linear molecule, such as a polymer, e.g. a polypeptide or a polyethylene glycol (PEG).
  • a spacer has a different structure from the target polynucleotide. For instance, if the target polynucleotide is DNA, the or each spacer typically does not comprise DNA.
  • the or each spacer preferably comprises peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), locked nucleic acid (LNA) or a synthetic polymer with nucleotide side chains.
  • PNA peptide nucleic acid
  • GNA glycerol nucleic acid
  • TAA threose nucleic acid
  • LNA locked nucleic acid
  • a spacer may comprise one or more nitroindoles, one or more inosines, one or more acridines, one or more 2-aminopurines, one or more 2-6-diaminopurines, one or more 5-bromo-deoxyuridines, one or more inverted thymidines (inverted dTs), one or more inverted dideoxy-thymidines (ddTs), one or more dideoxy-cytidines (ddCs), one or more 5 -methylcytidines, one or more 5- hydroxymethylcytidines, one or more 2’-O-Methyl RNA bases, one or more Iso- deoxycytidines (Iso-dCs), one or more Iso-deoxyguanosines (Iso-dGs), one or more C3 (OC 3 H 6 OPO 3 ) groups, one or more photo-cleavable (PC) [OC 3 H 6 -C
  • a spacer may comprise any combination of these groups. Many of these groups are commercially available from IDT® (Integrated DNA Technologies®). For example, C3, iSp9 and iSpl 8 spacers are all available from IDT®. A spacer may comprise any number of the above groups as spacer units.
  • a spacer may comprise one or more chemical groups, e.g. one or more pendant chemical groups.
  • the one or more chemical groups may be attached to one or more nucleobases in a polynucleotide adapter.
  • the one or more chemical groups may be attached to the backbone of a polynucleotide adapter. Any number of appropriate chemical groups may be present, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more.
  • Suitable groups include, but are not limited to, fhiorophores, streptavidin and/or biotin, cholesterol, methylene blue, dinitrophenols (DNPs), digoxigenin and/or anti-digoxigenin and dibenzylcyclooctyne groups.
  • a spacer may comprise one or more abasic nucleotides (i.e. nucleotides lacking a nucleobase), such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more abasic nucleotides.
  • the nucleobase can be replaced by -H (idSp) or -OH in the abasic nucleotide.
  • Abasic spacers can be inserted into target polynucleotides by removing the nucleobases from one or more adjacent nucleotides.
  • polynucleotides may be modified to include 3 -methyladenine, 7-methylguanine, 1 ,N6-ethenoadenine inosine or hypoxanthine and the nucleobases may be removed from these nucleotides using Human Alkyladenine DNA Glycosylase (hAAG).
  • polynucleotides may be modified to include uracil and the nucleobases removed with Uracil-DNA Glycosylase (UDG).
  • the one or more spacers do not comprise any abasic nucleotides.
  • Suitable spacers can be designed or selected depending on the nature of the polynucleotide or polynucleotide adapter, the polynucleotide-handling protein and the conditions under which the method is to be carried out.
  • a polynucleotide or an adapter attached thereto may comprise a membrane anchor or a transmembrane pore anchor e.g. attached to the adapter.
  • the anchor aids in characterisation of the polynucleotide in accordance with the methods disclosed herein.
  • a membrane anchor or transmembrane pore anchor may promote localisation of the polynucleotide around a nanopore in a membrane.
  • a polynucleotide or polynucleotide adapter may comprise a membrane anchor or a transmembrane pore anchor.
  • the anchor assists in the characterisation of a polynucleotide in accordance with the methods disclosed herein.
  • a membrane anchor or transmembrane pore anchor may promote localisation of the polynucleotides with a desired characteristic around a nanopore.
  • the anchor may be a polypeptide anchor and/or a hydrophobic anchor that can be inserted into the membrane.
  • the hydrophobic anchor is a lipid, fatty acid, sterol, carbon nanotube, polypeptide, protein or amino acid, for example cholesterol, palmitate or tocopherol.
  • the anchor may comprise thiol, biotin or a surfactant.
  • the anchor may be biotin (for binding to streptavidin), amylose (for binding to maltose binding protein or a fusion protein), Ni-NTA (for binding to poly-histidine or poly-histidine tagged proteins) or peptides (such as an antigen).
  • the anchor comprises a linker, or 2, 3, 4 or more linkers.
  • Preferred linkers include, but are not limited to, polymers, such as polynucleotides, polyethylene glycols (PEGs), polysaccharides and polypeptides. These linkers may be linear, branched or circular. For instance, the linker may be a circular polynucleotide. The adapter may hybridise to a complementary sequence on a circular polynucleotide linker.
  • the one or more anchors or one or more linkers may comprise a component that can be cut or broken down, such as a restriction site or a photolabile group.
  • the linker may be functionalised with maleimide groups to attach to cysteine residues in proteins. Suitable linkers are described in WO 2010/086602.
  • the anchor is cholesterol or a fatty acyl chain.
  • any fatty acyl chain having a length of from 6 to 30 carbon atom, such as hexadecanoic acid may be used.
  • suitable anchors and methods of attaching anchors to adapters are disclosed in WO 2012/164270 and WO 2015/150786.
  • the anchor may consist or comprise a hydrophobic modification to the polynucleotide or polynucleotide adapter.
  • the hydrophobic modification may comprise a modified phosphate group comprised within the polynucleotide or polynucleotide anchor.
  • the hydrophobic modification may for example comprise a phosphorothioate such as a charge-neutralized alkyl-phosphorothioate (PPT) as described in Jones et al, J. Am. Chem. Soc. 2021, 143, 22, 8305, the entire contents of which are hereby incorporated by reference.
  • Suitable alkyl groups include for example C 1 - C 10 alkyl groups such as C 2 -C 6 alkyl groups; e.g.
  • the translocation of the polynucleotide through the pore in the first direction and/or in the second direction with respect to the nanopore (preferably in the first direction) is controlled using a polynucleotide handling enzyme.
  • the polynucleotide-handling protein controls the movement of the polynucleotide in the same direction as the physical or chemical force (potential).
  • a positive voltage potential is applied to the trans side of the nanopore, and the polynucleotide-handling protein controls the movement of the construct from the cis side of the nanopore to the trans side of the nanopore.
  • a positive voltage potential is applied to the cis side of the nanopore relative to the trans side of the nanopore, and the polynucleotide-handling protein controls the movement of the construct from the trans side of the nanopore to the cis side of the nanopore.
  • the polynucleotide-handling protein controls the movement of the polynucleotide in the opposite direction to the physical or chemical force (potential).
  • a positive voltage potential is applied to the trans side of the nanopore, and the polynucleotide-handling protein controls the movement of the construct from the trans side of the nanopore to the cis side of the nanopore.
  • a positive voltage potential is applied to the cis side of the nanopore, and the polynucleotide-handling protein controls the movement of the construct from the cis side of the nanopore to the trans side of the nanopore.
  • the movement of the polynucleotide is driven by the polynucleotide-handling protein in the absence of an applied potential.
  • the disclosed methods comprise contacting the polynucleotide with a polynucleotide-handling protein capable of controlling the movement of the polynucleotide through the pore in the first direction and/or in the second direction with respect to the nanopore.
  • Suitable polynucleotide-handling proteins are also known as motor proteins or polynucleotide-handling enzymes. Suitable polynucleotide-handling proteins are known in the art and some exemplary polynucleotide-handling proteins are described in more detail below.
  • the polynucleotide-handling protein is, comprises, or is derived from a helicase, translocate or helicase-nuclease complex.
  • the polynucleotide-handling protein may be chosen or selected according to the polynucleotide to be used in the methods disclosed herein.
  • the polynucleotide may be chosen or selected according to the polynucleotide-handling protein used in the disclosed methods.
  • typically DNA motor proteins can be used when the polynucleotide is DNA.
  • RNA motor protein can be used when the polynucleotide is RNA.
  • Motor proteins which can process both DNA and RNA can be used when the polynucleotide is a hybrid of DNA and RNA.
  • the motor protein is derived from a member of any of the Enzyme Classification (EC) groups 3.1.11, 3.1.13, 3.1.14, 3.1.15, 3.1.16, 3.1.21, 3.1.22, 3.1.25, 3.1.26, 3.1.27, 3.1.30 and 3.1.31.
  • EC Enzyme Classification
  • the motor protein is a helicase, a polymerase, an exonuclease, a topoisomerase, or a variant thereof.
  • the motor protein is an exonuclease.
  • Suitable enzymes include, but are not limited to, exonuclease I from E. coli (SEQ ID NO: 1), exonuclease III enzyme from E. coli (SEQ ID NO: 2), Reel from T. thermophilus (SEQ ID NO: 3) and bacteriophage lambda exonuclease (SEQ ED NO: 4), TatD exonuclease and variants thereof.
  • Three subunits comprising the sequence shown in SEQ ID NO: 3 or a variant thereof interact to form a trimer exonuclease.
  • the motor protein is a polymerase.
  • the polymerase may be PyroPhage® 3173 DNA Polymerase (which is commercially available from Lucigen® Corporation), SD Polymerase (commercially available from Bioron®), Klenow from NEB or variants thereof.
  • the enzyme is Phi29 DNA polymerase (SEQ ID NO: 5) or a variant thereof. Modified versions of Phi29 polymerase that may be used in the disclosed methods are disclosed in US Patent No. 5,576,204.
  • the polynucleotide-handling protein is typically a polymerase, e.g. a polymerase as described herein.
  • the polynucleotide-handling protein is a topoisomerase.
  • the topoisomerase is a member of any of the Moiety Classification (EC) groups 5.99.1.2 and 5.99.1.3.
  • the topoisomerase may be a reverse transcriptase, which are enzymes capable of catalysing the formation of cDNA from a RNA template. They are commercially available from, for instance, New England Biolabs® and Invitrogen®.
  • polynucleotide-handling protein is a translocase.
  • translocases in the FtsK and SpoIII families include translocases in the FtsK and SpoIII families.
  • the polynucleotide-handling protein is a helicase.
  • Any suitable helicase can be used in accordance with the methods provided herein.
  • the or each motor protein used in accordance with the present disclosure may be independently selected from a Hel308 helicase, a RecD helicase, a Tral helicase, a TrwC helicase, an XPD helicase, and a Dda helicase, or a variant thereof.
  • Monomeric helicases may comprise several domains attached together. For instance, Tral helicases and Tral subgroup helicases may contain two RecD helicase domains, a relaxase domain and a C- terminal domain.
  • the domains typically form a monomeric helicase that is capable of functioning without forming oligomers.
  • suitable helicases include Hel308, NS3, Dda, UvrD, Rep, PcrA, Pifl and Tral. These helicases typically work on single stranded DNA.
  • Examples of helicases that can move along both strands of a double stranded DNA include FtsK and hexameric enzyme complexes, or multisubunit complexes such as RecBCD, and are particularly suited to some embodiments disclosed herein.
  • NS3 helicases are particularly suitable for use in the disclosed methods as they are capable of processing both DNA and RNA and so can be used in embodiments of the disclosed methods in which the target double stranded nucleic acid is a DNA-RNA hybrid.
  • Hel308 helicases are described in publications such as WO 2013/057495, the entire contents of which are incorporated by reference.
  • RecD helicases are described in publications such as WO 2013/098562, the entire contents of which are incorporated by reference.
  • XPD helicases are described in publications such as WO 2013/098561, the entire contents of which are incorporated by reference.
  • Dda helicases are described in publications such as WO 2015/055981 and WO 2016/055777, the entire contents of each of which are incorporated by reference.
  • the helicase comprises the sequence shown in SEQ ID NO: 6 (Trwc Cba) or a variant thereof, the sequence shown in SEQ ID NO: 7 (Hel308 Mbu) or a variant thereof or the sequence shown in SEQ ID NO: 8 (Dda) or a variant thereof.
  • Variants may differ from the native sequences in any of the ways discussed herein.
  • An example variant of SEQ ID NO: 8 comprises E94C/A360C.
  • a further example variant of SEQ ID NO: 8 comprises E94C/A360C and then (AM1)G1G2 (i.e. deletion of Ml and then addition of G1 and G2).
  • a motor protein e.g. a helicase
  • the motor protein moves along the polynucleotide in a 5’ to 3’ or a 3’ to 5’ direction (depending on the motor protein).
  • the motor protein can be used to either move the polynucleotide away from (e.g. out of) the pore (e.g. against an applied force) or towards (e.g. into) the pore (e.g. with an applied force).
  • the motor protein works against the direction of the force and pulls the threaded strand out of the pore (e.g. into the cis chamber).
  • the motor protein works with the direction of the force and pushes the threaded strand into the pore (e.g. into the trans chamber).
  • the motor protein e.g. helicase
  • the motor protein can bind to the polynucleotide and act as a brake slowing the movement of the strand when it is moved with respect to a nanopore, e.g. by being pulled into the pore by a force.
  • the inactive mode it does not matter which end of the strand is captured, it is the applied force which determines the movement with respect to the pore, and the polynucleotide binding protein acts as a brake.
  • the movement control by the polynucleotide binding protein can be described in a number of ways including ratcheting, sliding and braking.
  • a motor protein typically requires fuel in order to handle the processing of polynucleotides.
  • Fuel is typically free nucleotides or free nucleotide analogues.
  • the free nucleotides may be one or more of, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), cyclic adenosine monophosphate (c
  • the free nucleotides are usually selected from AMP, TMP, GMP, CMP, UMP, dAMP, dTMP, dGMP or dCMP.
  • the free nucleotides are typically adenosine triphosphate (ATP).
  • a cofactor for the motor protein is a factor that allows the motor protein to function.
  • the cofactor is preferably a divalent metal cation.
  • the divalent metal cation is preferably Mg 2+ , Mn 2+ , Ca 2+ or Co 2+ .
  • the cofactor is most preferably Mg 2 *.
  • any suitable nanopore can be used.
  • the nanopore is a protein pore, a solid state pore or a DNA origami pore.
  • the nanopore is a transmembrane pore, such as a transmembrane protein pore.
  • the pore may be biological or artificial.
  • a transmembrane pore is a structure that crosses the membrane to some degree. It permits hydrated ions driven by an applied potential to flow across or within the membrane.
  • the transmembrane pore typically crosses the entire membrane so that hydrated ions may flow from one side of the membrane to the other side of the membrane.
  • the transmembrane pore does not have to cross the membrane. It may be closed at one end.
  • the pore may be a well, gap, channel, trench or slit in the membrane along which or into which hydrated ions may flow.
  • the pore may be a DNA origami pore (Langecker et al., Science, 2012; 338: 932-936). Suitable DNA origami pores are disclosed in WO2013/083983, WO 2018/011603 and WO 2020/025974, each of which is incorporated by reference in their entirety.
  • the transmembrane protein pore comprises a barrel or channel through which the ions may flow.
  • the subunits of the pore typically surround a central axis and contribute strands to a transmembrane p-barrel or channel or a transmembrane a- helix bundle or channel.
  • the barrel or channel of the transmembrane protein pore comprises amino acids that facilitate interaction with an analyte, such as a target polynucleotide (as described herein). These amino acids are preferably located near a constriction of the barrel or channel.
  • the transmembrane protein pore typically comprises one or more positively charged amino acids, such as arginine, lysine or histidine, or aromatic amino acids, such as tyrosine or tryptophan. These amino acids typically facilitate the interaction between the pore and nucleotides, polynucleotides or nucleic acids.
  • the nanopore is a transmembrane protein pore derived from P- barrel pores or a-helix bundle pores
  • p-barrel pores comprise a barrel or channel that is formed from p-strands.
  • Suitable P-barrel pores include, but are not limited to, P-toxins, such as a-hemolysin, anthrax toxin and leukocidins, and outer membrane proteins/porins of bacteria, such as Mycobacterium smegmatis porin (Msp), for example MspA, MspB, MspC or MspD, CsgG, outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A and Neisseria autotransporter lipoprotein (NalP) and other pores, such as lysenin.
  • a-helix bundle pores comprise a barrel or channel that is formed from a-helices.
  • Suitable a-helix bundle pores include,
  • the nanopore is a transmembrane pore derived from or based on Msp, a-hemolysin (a-HL), lysenin, CsgG, ClyA, Spl or haemolytic protein fragaceatoxin C (FraC).
  • the nanopore is a transmembrane protein pore derived from CsgG, e.g. from CsgG from E. coli Str. K-12 substr. MC4100.
  • a pore is oligomeric and typically comprises 7, 8, 9 or 10 monomers derived from CsgG.
  • the pore may be a homo-oligomeric pore derived from CsgG comprising identical monomers.
  • the pore may be a hetero-oligomeric pore derived from CsgG comprising at least one monomer that differs from the others.
  • the nanopore is a transmembrane pore derived from lysenin.
  • suitable pores derived from lysenin are disclosed in WO 2013/153359, which is hereby incorporated by reference in its entirety.
  • the nanopore is a transmembrane pore derived from or based on a-hemolysin ( ⁇ -HL).
  • the wild type a-hemolysin pore is formed of 7 identical monomers or sub-units (i.e., it is heptameric).
  • An a-hemolysin pore may be a-hemolysin- NN or a variant thereof.
  • the variant preferably comprises N residues at positions El 11 andK147.
  • the nanopore is a transmembrane protein pore derived from Msp, e.g. from MspA.
  • Msp transmembrane protein pore derived from Msp
  • suitable pores derived from MspA are disclosed in WO 2012/107778.
  • the nanopore is selected from M-ring protein, perforin-2, PlyAB (pleurotolysin), SpoIIIAG, VirB7, Type II secretion system protein D, GspD, InvG, PilQ, pentraxin, and portal proteins including T4, T7, P23 45, G20c and Phi29 nanopores.
  • the nanopore is a transmembrane pore derived from or based on a Rhodococcus species of bacteria, for example Rhodococcus corynebacteroides or Rhodococcus ruber, for example PorARr, PorBRr or PorARc. Examples of such pores are described in Piselli et al., Eur Biophys J 51, 309-323 (2022).
  • the nanopore is typically a nanopore present in a membrane. Any suitable membrane may be used.
  • the membrane is preferably an amphiphilic layer.
  • An amphiphilic layer is a layer formed from amphiphilic molecules, such as phospholipids, which have both hydrophilic and lipophilic properties.
  • the amphiphilic molecules may be synthetic or naturally occurring.
  • Non-naturally occurring amphiphiles and amphiphiles which form a monolayer are known in the art and include, for example, block copolymers (Gonzalez-Perez et al., Langmuir, 2009, 25, 10447-10450).
  • Block copolymers are polymeric materials in which two or more monomer sub-units that are polymerized together to create a single polymer chain. Block copolymers typically have properties that are contributed by each monomer sub-unit.
  • a block copolymer may have unique properties that polymers formed from the individual sub-units do not possess.
  • Block copolymers can be engineered such that one of the monomer sub-units is hydrophobic (i.e. lipophilic), whilst the other sub- unit(s) are hydrophilic whilst in aqueous media.
  • the block copolymer may possess amphiphilic properties and may form a structure that mimics a biological membrane.
  • the block copolymer may be a diblock (consisting of two monomer subunits), but may also be constructed from more than two monomer sub-units to form more complex arrangements that behave as amphipiles.
  • the copolymer may be a triblock, tetrablock or pentablock copolymer.
  • the membrane is preferably a triblock copolymer membrane.
  • Archaebacterial bipolar tetraether lipids are naturally occurring lipids that are constructed such that the lipid forms a monolayer membrane. These lipids are generally found in extremophiles that survive in harsh biological environments, thermophiles, halophiles and acidophiles. Their stability is believed to derive from the fused nature of the final bilayer. It is straightforward to construct block copolymer materials that mimic these biological entities by creating a triblock polymer that has the general motif hydrophilic-hydrophobic-hydrophilic. This material may form monomeric membranes that behave similarly to lipid bilayers and encompass a range of phase behaviours from vesicles through to laminar membranes. Membranes formed from these triblock copolymers hold several advantages over biological lipid membranes. Because the triblock copolymer is synthesised, the exact construction can be carefully controlled to provide the correct chain lengths and properties required to form membranes and to interact with pores and other proteins.
  • Block copolymers may also be constructed from sub-units that are not classed as lipid sub-materials; for example a hydrophobic polymer may be made from siloxane or other non-hydrocarbon based monomers.
  • the hydrophilic sub-section of block copolymer can also possess low protein binding properties, which allows the creation of a membrane that is highly resistant when exposed to raw biological samples.
  • This head group unit may also be derived from non-classical lipid head-groups.
  • Triblock copolymer membranes also have increased mechanical and environmental stability compared with biological lipid membranes, for example a much higher operational temperature or pH range. The synthetic nature of the block copolymers provides a platform to customise polymer based membranes for a wide range of applications.
  • the membrane is one of the membranes disclosed in International Application No. WO2014/064443 or WO2014/064444.
  • the amphiphilic molecules may be chemically-modified or functionalised to facilitate coupling of the polynucleotide.
  • the amphiphilic layer may be a monolayer or a bilayer.
  • the amphiphilic layer is typically planar.
  • the amphiphilic layer may be curved.
  • the amphiphilic layer may be supported.
  • Amphiphilic membranes are typically naturally mobile, essentially acting as two dimensional fluids with lipid diffusion rates of approximately 10 -8 cm s -1 . This means that the pore and coupled polynucleotide can typically move within an amphiphilic membrane.
  • the membrane may be a lipid bilayer. Lipid bilayers are models of cell membranes and serve as excellent platforms for a range of experimental studies. For example, lipid bilayers can be used for in vitro investigation of membrane proteins by single-channel recording. Alternatively, lipid bilayers can be used as biosensors to detect the presence of a range of substances.
  • the lipid bilayer may be any lipid bilayer. Suitable lipid bilayers include, but are not limited to, a planar lipid bilayer, a supported bilayer or a liposome.
  • the lipid bilayer is preferably a planar lipid bilayer. Suitable lipid bilayers are disclosed in WO 2008/102121, WO 2009/077734 and WO 2006/100484.
  • Lipid bilayers are commonly formed by the method of Montal and Mueller (Proc. Natl. Acad. Sci. USA-, 1972; 69: 3561-3566), in which a lipid monolayer is carried on aqueous solution/air interface past either side of an aperture which is perpendicular to that interface.
  • the lipid is normally added to the surface of an aqueous electrolyte solution by first dissolving it in an organic solvent and then allowing a drop of the solvent to evaporate on the surface of the aqueous solution on either side of the aperture. Once the organic solvent has evaporated, the solution/air interfaces on either side of the aperture are physically moved up and down past the aperture until a bilayer is formed.
  • Planar lipid bilayers may be formed across an aperture in a membrane or across an opening into a recess.
  • Montal & Mueller The method of Montal & Mueller is popular because it is a cost-effective and relatively straightforward method of forming good quality lipid bilayers that are suitable for protein pore insertion.
  • Other common methods of bilayer formation include tipdipping, painting bilayers and patch-clamping of liposome bilayers.
  • Tip-dipping bilayer formation entails touching the aperture surface (for example, a pipette tip) onto the surface of a test solution that is carrying a monolayer of lipid. Again, the lipid monolayer is first generated at the solution/air interface by allowing a drop of lipid dissolved in organic solvent to evaporate at the solution surface. The bilayer is then formed by the Langmuir- Schaefer process and requires mechanical automation to move the aperture relative to the solution surface.
  • the aperture surface for example, a pipette tip
  • lipid dissolved in organic solvent is applied directly to the aperture, which is submerged in an aqueous test solution.
  • the lipid solution is spread thinly over the aperture using a paintbrush or an equivalent. Thinning of the solvent results in formation of a lipid bilayer.
  • complete removal of the solvent from the bilayer is difficult and consequently the bilayer formed by this method is less stable and more prone to noise during electrochemical measurement.
  • Patch-clamping is commonly used in the study of biological cell membranes.
  • the cell membrane is clamped to the end of a pipette by suction and a patch of the membrane becomes attached over the aperture.
  • the method has been adapted for producing lipid bilayers by clamping liposomes which then burst to leave a lipid bilayer sealing over the aperture of the pipette.
  • the method requires stable, giant and unilamellar liposomes and the fabrication of small apertures in materials having a glass surface.
  • Liposomes can be formed by sonication, extrusion or the Mozafari method (Colas et al. (2007) Micron 38:841-847).
  • a lipid bilayer is formed as described in International Application No. WO 2009/077734.
  • the lipid bilayer is formed from dried lipids.
  • the lipid bilayer is formed across an opening as described in W02009/077734.
  • a lipid bilayer is formed from two opposing layers of lipids.
  • the two layers of lipids are arranged such that their hydrophobic tail groups face towards each other to form a hydrophobic interior.
  • the hydrophilic head groups of the lipids face outwards towards the aqueous environment on each side of the bilayer.
  • the bilayer may be present in a number of lipid phases including, but not limited to, the liquid disordered phase (fluid lamellar), liquid ordered phase, solid ordered phase (lamellar gel phase, interdigitated gel phase) and planar bilayer crystals (lamellar sub-gel phase, lamellar crystalline phase). Any lipid composition that forms a lipid bilayer may be used.
  • the lipid composition is chosen such that a lipid bilayer having the required properties, such surface charge, ability to support membrane proteins, packing density or mechanical properties, is formed.
  • the lipid composition can comprise one or more different lipids.
  • the lipid composition can contain up to 100 lipids.
  • the lipid composition preferably contains 1 to 10 lipids.
  • the lipid composition may comprise naturally-occurring lipids and/or artificial lipids.
  • the lipids typically comprise a head group, an interfacial moiety and two hydrophobic tail groups which may be the same or different.
  • Suitable head groups include, but are not limited to, neutral head groups, such as diacylglycerides (DG) and ceramides (CM); zwitterionic head groups, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin (SM); negatively charged head groups, such as phosphatidylglycerol (PG); phosphatidylserine (PS), phosphatidylinositol (PI), phosphatic acid (PA) and cardiolipin (CA); and positively charged headgroups, such as trimethylammonium-Propane (TAP).
  • neutral head groups such as diacylglycerides (DG) and ceramides (CM)
  • zwitterionic head groups such as phosphatidylcholine (PC), phosphatidylethanolamine (PE
  • Suitable interfacial moieties include, but are not limited to, naturally-occurring interfacial moieties, such as glycerol-based or ceramide- based moieties.
  • Suitable hydrophobic tail groups include, but are not limited to, saturated hydrocarbon chains, such as lauric acid (w-Dodecanolic acid), myristic acid (n- Tetradecononic acid), palmitic acid (n-Hexadecanoic acid), stearic acid (n-Octadecanoic) and arachidic (w-Eicosanoic); unsaturated hydrocarbon chains, such as oleic acid (cis-9- Octadecanoic); and branched hydrocarbon chains, such as phytanoyl.
  • the length of the chain and the position and number of the double bonds in the unsaturated hydrocarbon chains can vary.
  • the length of the chains and the position and number of the branches, such as methyl groups, in the branched hydrocarbon chains can vary.
  • the hydrophobic tail groups can be linked to the interfacial moiety as an ether or an ester.
  • the lipids may be mycolic acid.
  • the lipids can also be chemically-modified.
  • the head group or the tail group of the lipids may be chemically-modified.
  • Suitable lipids whose head groups have been chemically-modified include, but are not limited to, PEG-modified lipids, such as 1,2- Diacyl-sn-Glycero-3-Phosphoethanolamine-N -[Methoxy(Polyethylene glycol)-2000]; functionalised PEG Lipids, such as 1,2-Distearoyl-sn-Glycero-3 Phosphoethanolamine-N- [Biotinyl(Polyethylene Glycol)2000]; and lipids modified for conjugation, such as 1,2- Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-(succinyl) and 1,2-Dipalmitoyl-sn- Glycero-3-Phosphoethanolamine-N-(Biotinyl).
  • Suitable lipids whose tail groups have been chemically-modified include, but are not limited to, polymerisable lipids, such as 1,2- bis(10,12-tricosadiynoyl)-sn-Glycero-3-Phosphocholine; fluorinated lipids, such as 1- Palmitoyl-2-(16-Fluoropalmitoyl)-sn-Glycero-3-Phosphocholine; deuterated lipids, such as 1,2-Dipalmitoyl-D62-sn-Glycero-3-Phosphocholine; and ether linked lipids, such as 1,2- Di-O-phytanyl-sn-Glycero-3-Phosphocholine.
  • the lipids may be chemically-modified or functionalised to facilitate coupling of the polynucleotide.
  • the amphiphilic layer typically comprises one or more additives that will affect the properties of the layer.
  • Suitable additives include, but are not limited to, fatty acids, such as palmitic acid, myristic acid and oleic acid; fatty alcohols, such as palmitic alcohol, myristic alcohol and oleic alcohol; sterols, such as cholesterol, ergosterol, lanosterol, sitosterol and stigmasterol; lysophospholipids, such as 1-Acyl-2-Hydroxy-sn- Glycero-3 -Phosphocholine; and ceramides.
  • the membrane comprises a solid state layer.
  • Solid state layers can be formed from both organic and inorganic materials including, but not limited to, microelectronic materials, insulating materials such as SisN4, AI2O3, and SiO, organic and inorganic polymers such as polyamide, plastics such as Teflon® or elastomers such as two-comporient addition-cure silicone rubber, and glasses.
  • the solid state layer may be formed from graphene. Suitable graphene layers are disclosed in WO 2009/035647.
  • the membrane comprises a solid state layer, the pore is typically present in an amphiphilic membrane or layer contained within the solid state layer, for instance within a hole, well, gap, channel, trench or slit within the solid state layer.
  • suitable solid state/amphiphilic hybrid systems Suitable systems are disclosed in WO 2009/020682 and WO 2012/005857. Any of the amphiphilic membranes or layers discussed above may be used.
  • the methods disclosed herein are typically carried out using (i) an artificial amphiphilic layer comprising a pore, (ii) an isolated, naturally-occurring lipid bilayer comprising a pore, or (iii) a cell having a pore inserted therein.
  • the methods are typically carried out using an artificial amphiphilic layer, such as an artificial triblock copolymer layer.
  • the layer may comprise other transmembrane and/or intramembrane proteins as well as other molecules in addition to the pore. Suitable apparatus and conditions are discussed below.
  • the method of the invention is typically carried out in vitro. General methods
  • the methods provided herein may be operated using any suitable nanopore, and as such any suitable nanopore apparatus for detecting polynucleotides can be used.
  • the methods provided herein may in some embodiments be carried out using any apparatus that is suitable for transmembrane pore sensing.
  • the apparatus may comprise a chamber comprising an aqueous solution and a barrier that separates the chamber into two sections.
  • the barrier may have an aperture in which a membrane containing a transmembrane pore is formed. Transmembrane pores are described herein.
  • the binding of a molecule in the channel of a pore will have an effect on the open-channel ion flow through the pore, which is the essence of “molecular sensing” of pore channels.
  • Variation in the open-channel ion flow can be measured using suitable measurement techniques by the change in electrical current.
  • the degree of reduction in ion flow, as measured by the reduction in electrical current is related to the size of the obstruction within, or in the vicinity of, the pore. Binding of a molecule of interest (e.g.
  • the target polynucleotide) in or near the pore therefore provides a detectable and measurable event, thereby forming the basis of a “biological sensor”. Detecting the presence of biological molecules finds application in personalised drug development, medicine, diagnostics, life science research, environmental monitoring and in the security and/or the defence industry.
  • the methods may involve measuring the ion current flow through the pore, typically by measurement of a current.
  • the ion flow through the pore may be measured optically, such as disclosed by Heron et al: J. Am. Chem. Soc. 9 Vol. 131, No. 5, 2009. Therefore, the apparatus may also comprise an electrical circuit capable of applying a potential and measuring an electrical signal across the membrane and pore.
  • the characterisation methods may be carried out using a patch clamp or a voltage clamp. The characterisation methods preferably involve the use of a voltage clamp.
  • the methods may involve measuring an optical signal as described in Chen et al, Nature Communications (2018)9:1733, the entire contents of which are hereby incorporated by reference.
  • a nanopore such as an optically engineered nanopore structure (e.g. a plasmonic nanoslit) may be used to locally enable single- molecule surface enhanced Raman spectroscopy (SERS) to allow the characterisation of the polynucleotide through direct Raman spectroscopic detection.
  • SERS surface enhanced Raman spectroscopy
  • the methods may be carried out on a silicon-based array of wells where each array comprises 128, 256, 512, 1024, 2000, 3000, 4000, 6000, 10000, 12000, 15000 or more wells.
  • the methods may involve the measuring of a current flowing through the pore.
  • the method is typically carried out with a voltage applied across the membrane and pore.
  • the voltage used is typically from +2 V to -2 V, typically -400 mV to +400mV.
  • the voltage used is preferably in a range having a lower limit selected from -400 mV, -300 mV, -200 mV, -150 mV, -100 mV, -50 mV, -20mV and 0 mV and an upper limit independently selected from +10 mV, + 20 mV, +50 mV, +100 mV, +150 mV, +200 mV, +300 mV and +400 mV.
  • the voltage used is more preferably in the range 100 mV to 240mV and most preferably in the range of 120 mV to 220 mV. It is possible to increase discrimination between different nucleotides by a pore by using an increased applied potential.
  • the voltage is applied across the nanopore via one or more electrodes. In some embodiments, the voltage is applied across the nanopore via one or more platinum electrodes. In some embodiments the voltage is applied across the nanopore via one or more platinum electrodes and the conditions which decrease formation of cation-mediated secondary structure comprise the use of sodium chloride and sodium ferricyanide/sodium ferrocyanide salts. Surprisingly, such conditions are compatible.
  • the methods are typically carried out in the presence of any charge carriers, such as metal salts, for example alkali metal salts, halide salts, for example chloride salts, such as alkali metal chloride salt.
  • Charge carriers may include ionic liquids or organic salts, for example tetramethyl ammonium chloride, trimethylphenyl ammonium chloride, phenyltrimethyl ammonium chloride, or 1- ethyl-3 -methyl imidazolium chloride.
  • the salt is present in the aqueous solution in the chamber.
  • the salts typically used as charge carriers are described herein and above.
  • the methods are typically carried out in the presence of a buffer.
  • the buffer is present in the aqueous solution in the chamber.
  • Any suitable buffer may be used.
  • the buffer is HEPES.
  • Another suitable buffer is Tris-HCl buffer.
  • the methods are typically carried out at a pH of from 4.0 to 12.0, from 4.5 to 10.0, from 5.0 to 9.0, from 5.5 to 8.8, from 6.0 to 8.7 or from 7.0 to 8.8 or 7.5 to 8.5.
  • the pH used is preferably about 7.5.
  • the methods comprise providing a condition which decreases formation of cation-mediated secondary structure.
  • the nanopore is disposed in said condition.
  • the method involves operating the nanopore by translocating a portion of a polynucleotide through the nanopore.
  • the method involves operating the nanopore by translocating a portion of a polynucleotide through the nanopore under conditions such that blocking of the nanopore is inhibited.
  • the nanopore is present in a nanopore array.
  • the nanopore array comprises a plurality of nanopores.
  • provided herein are methods of operating a nanopore array.
  • the methods comprise providing a condition which decreases formation of cation-mediated secondary structure in polynucleotides that may be contacted with the array.
  • the method involves operating the array by contacting a plurality of polynucleotides with the array and translocating a portion of each polynucleotide through the array.
  • the method involves operating the array by translocating a portion of a polynucleotide through the nanopore under conditions such that blocking of the nanopores in the array is inhibited.
  • the methods involve increasing the lifetime of the array.
  • the or each nanopore is a nanopore as described in more detail herein.
  • the polynucleotide is a polynucleotide as described herein.
  • the conditions are as described herein.
  • methods of unblocking a nanopore such as a nanopore in a nanopore array.
  • the methods are methods of unblocking a nanopore which is blocked by a polynucleotide.
  • the methods comprise contacting the nanopore with providing a condition which decreases formation of cation-mediated secondary structure, such as a condition as described herein.
  • the methods described herein are methods of increasing the usable lifetime of a nanopore. In some embodiments, the methods described herein methods of increasing the lifetime of a nanopore array. In some embodiments the lifetime of the nanopore or nanopore array is increased by reducing the blocking of the nanopore or of the nanopores in the array. In some embodiments the lifetime of the nanopore or array is increased by contacting the nanopore or array with a condition which decreases formation of cation-mediated secondary structure, such as a condition as described herein In some embodiments, the methods described herein are methods of increasing the efficiency of polynucleotide characterisation by a nanopore or a nanopore array.
  • the methods described herein are methods of increasing the efficiency of the operation of a nanopore or a nanopore array.
  • the methods involve increasing the efficiency of polynucleotide characterisation by decreasing blocking of the nanopore or of nanopores in the array.
  • the efficiency of characterisation is increased by contacting the nanopore or array with a condition which decreases formation of cation-mediated secondary structure, such as a condition as described herein
  • the or each nanopore may be a nanopore as described in more detail herein.
  • the or each polynucleotide is a polynucleotide as described herein. In some embodiments the conditions are as described herein.
  • kits comprising (a) a nanopore in a membrane and (b) one or more conditions as described herein, such as a solution comprising one or more conditions as described herein. Also provided is a kit comprising (a) a nanopore in a membrane and (b) a solution comprising a sodium ferricyanide/sodium ferrocyanide salt. Further provided is a kit comprising (a) a nanopore in a membrane and (b) a solution comprising one or more metal salts selected from the group consisting of one or more rubidium salts, sodium ferricyanide and sodium ferrocyanide.
  • the one or more metal salts are selected from the group consisting of (i) rubidium ferricyanide and/or rubidium ferrocyanide, (ii) rubidium chloride, and (iii) sodium ferricyanide and sodium ferrocyanide.
  • the one or more conditions comprise a salt comprising an ammonium cation and/or a metal salt as described herein.
  • the salt comprising an ammonium cation comprises (i) ammonium ferricyanide and/or ammonium ferrocyanide, and/or (ii) ammonium chloride.
  • the rubidium salt is rubidium chloride. It will be understood that any of the conditions, nanopores, polynucleotide-handling enzymes, anchors and adaptors can be applied to the kit discussed herein and above.
  • the kit further comprises a charge carrier as described herein.
  • the charge carrier is a further metal salt.
  • the further metal salt is not a potassium salt.
  • the further metal salt comprises a cation selected from the group consisting of Na*, Cs + , Li + , Mg 24- and Ca 2+ , typically Na + .
  • the further metal salt comprises a cation selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2 * and Ca 2 *, typically Rb + or Na + .
  • the further metal salt is a chloride salt.
  • the further metal salt is a chloride salt comprising a cation selected from the group consisting of Na + , Cs + , Li + , Mg 2 * and Ca 2 *, typically Na*.
  • the further metal salt is a chloride salt comprising a cation selected from the group consisting of Rb*, Na*, Cs*, Li* Mg 2 * and Ca 2 *, typically Rb* or Na*.
  • the further metal salt is RbCl.
  • the further metal salt is NaCl.
  • the further metal salt may comprise a potassium salt, such as KC1.
  • the kit further comprises a polynucleotide-handling enzyme as described herein.
  • the kit further comprises an anchor as described herein.
  • the kit further comprises an adaptor as described herein.
  • the nanopore in the kit may be comprised in one or more independently addressable elements as further described herein, wherein each independently addressable element comprises a cis and a trans chamber connected by an electrical communication means, wherein said cis and trans chambers are separated by the membrane comprising the nanopore.
  • an apparatus comprising (a) an array of nanopores in a membrane and (b) one or more conditions, as described herein, in contact with the membrane. Also provided is an apparatus comprising (a) an array of nanopores in a membrane and (b) a sodium ferricyanide/sodium ferrocyanide salt solution in contact with the membrane. Further provided is an apparatus comprising (a) an array of nanopores in a membrane and (b) a solution comprising one or more metal salts in contact with the membrane, wherein the one or more metal salts are selected from the group consisting of one or more rubidium salts, sodium ferricyanide and sodium ferrocyanide.
  • the one or more metal salts are selected from the group consisting of (i) rubidium ferricyanide and/or rubidium ferrocyanide, (ii) rubidium chloride, and (iii) sodium ferricyanide and sodium ferrocyanide.
  • the one or more conditions comprise a salt comprising an ammonium cation and/or a metal salt as described herein.
  • the salt comprising an ammonium cation comprises (i) ammonium ferricyanide and/or ammonium ferrocyanide, and/or (ii) ammonium chloride. It will be understood that any of the conditions, nanopores, polynucleotide-handling enzymes, anchors and adaptors can be applied to the apparatus discussed herein and above.
  • the apparatus further comprises a charge carrier as described herein.
  • the charge carrier is a further metal salt.
  • the further metal salt is not a potassium salt.
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2 h and Ca 2+ , typically Rb + or Na + .
  • the further metal salt comprises a cation selected from the group consisting of Na + , Cs + , Li + , Mg 2 * and Ca 2+ , typically Na + .
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , and Ca 2+ . In some embodiments, the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + and Li + , and Ca 2+ . In some embodiments, the further metal salt is a chloride salt. In some embodiments, the further metal salt comprises a chloride salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2 * and Ca 2+ , typically Rb + or Na + .
  • the further metal salt is a chloride salt comprising a cation selected from the group consisting of Na + , Cs + , Li*, Mg 2+ and Ca 2+ , typically Na + .
  • the further metal salt comprises a chloride salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + and Ca 2+ .
  • the further metal salt is a chloride salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + and Li + .
  • the further metal salt is RbCl.
  • the further metal salt is NaCl.
  • the apparatus further comprises a polynucleotide-handling enzyme as described herein. In some embodiments, the apparatus further comprises an anchor as described herein. In some embodiments, the apparatus further comprises an adaptor as described herein.
  • the array of nanopores in a membrane may be an array of individually addressable elements, wherein each independently addressable element of the array comprises a cis and a trans chamber connected by an electrical communication means, wherein said cis and trans chambers are separated by the membrane, and the membrane of each independently addressable element comprises a single nanopore.
  • the cis and the trans chamber each comprise the solution.
  • the trans chamber is substantially free of a potassium cation.
  • the trans chamber and the cis chamber is substantially free of a potassium cation.
  • the trans chamber comprises the solution, and the cis chamber comprises a different solution comprising one or more metal salts.
  • the cis chamber may or may not comprise conditions which decrease the formation of cation-mediated secondary structure.
  • the cis chamber may comprise a metal salt comprising a potassium cation.
  • the apparatus comprises a polynucleotide handling enzyme on the cis side of the membrane.
  • the independently addressable elements of the array share a common cis chamber.
  • each independently addressable element has a trans chamber separate from the trans chambers of other independently addressable elements of the array.
  • the apparatus comprises a voltage source connected to electrodes, wherein the voltage source and electrodes are configured to apply an electric field between the cis and the trans chambers.
  • the apparatus comprises a digital logic circuit associated with the nanopores of the independently addressable elements of the array of independently addressable elements. Such configurations of the apparatus are described in more detail in WO 2008/124107 Al.
  • the independently addressable elements of the array share a common cis electrode.
  • each independently addressable element has a trans electrode separate from the trans electrode of other independently addressable elements of the array.
  • the apparatus comprises a cis buffer in contact with the cis electrode.
  • the cis buffer comprises a metal salt, such as a metal salt comprising one or more cations selected from the group consisting of K + , Rb + , Na + , Cs + , Li + , Mg 2 * and Ca 2+ , typically K + , Rb + or Na + .
  • the trans buffer is substantially free of a potassium cation.
  • the trans buffer comprises a metal salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 24 * and Ca 2+ , typically Rb + or Na + .
  • the kit and apparatus disclosed herein may be configured for use with an algorithm, also provided herein, adapted to be run on a computer system.
  • the algorithm may be adapted to detect information characteristic of a polynucleotide (e.g. characteristic of the sequence of the polynucleotide), and to selectively process the signal obtained as the polynucleotide moves with respect to a nanopore.
  • an apparatus comprising computing means configured to detect information characteristic of a polynucleotide (e.g. characteristic of the sequence of the polynucleotide) and to selectively process the signal obtained as the polynucleotide moves with respect to the nanopore.
  • the system comprises receiving means for receiving data from detection of the polynucleotide, processing means for processing the signal obtained as the polynucleotide moves with respect to the nanopore, and output means for outputting the characterisation information thus obtained.
  • a sodium salt for reducing cation-mediated secondary structure in a polynucleotide in a nanopore apparatus or during a method of characterising a polynucleotide using a nanopore is also provided herein.
  • one or more metal salts for reducing cation-mediated secondary structure in a polynucleotide in a nanopore apparatus or during a method of characterising a polynucleotide using a nanopore wherein the one or more metal salts are selected from the group consisting of one or more rubidium salts, sodium ferricyanide and sodium ferrocyanide. It will be understood that any of the methods, conditions, nanopores, polynucleotide-handling enzymes, anchors, adaptors and apparatuses can be applied to the use discussed herein and above.
  • the sodium salt is a sodium ferricyanide/sodium ferrocyanide salt solution.
  • the sodium salt further comprises a charge carrier as described herein.
  • the one or more metal salts are selected from the group consisting of (i) rubidium ferricyanide and/or rubidium ferrocyanide, (ii) rubidium chloride, and (iii) sodium ferricyanide and sodium ferrocyanide.
  • the rubidium salt further comprises a charge carrier as described herein.
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 24 and Ca 2+ , typically Rb + or Na + .
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + and Ca 2+ .
  • the further metal salt comprises one or more cations selected from the group consisting of Rb + , Na + , Cs + and Li + .
  • the charge carrier is a further metal salt.
  • the further metal salt is not a potassium salt.
  • the further metal salt comprises a cation selected from the group consisting of Na + , Cs + , Li + , Mg 24 and Ca 2+ , typically Na + .
  • the further metal salt is a chloride salt.
  • the further metal salt comprises a chloride salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + , Mg 2+ and Ca 2+ , typically Rb + or Na + .
  • the further metal salt is a chloride salt comprising a cation selected from the group consisting of Na + , Cs + , Li + , Mg 2+ and Ca 2+ , typically Na + .
  • the further metal salt comprises a chloride salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + , Li + and Ca 2+ . In some embodiments, the further metal salt comprises a chloride salt comprising one or more cations selected from the group consisting of Rb + , Na + , Cs + and Li + . In some embodiments the further metal salt is RbCl. In some embodiments the further metal salt is NaCl.
  • the sodium salt is used in any of the methods described herein. In some embodiments, the sodium salt is used in any of the apparatuses described herein. In some embodiments, the rubidium salt is used in any of the methods described herein. In some embodiments, the rubidium salt is used in any of the apparatuses described herein.
  • a sample comprising human genomic DNA 30 kb in length was prepared and added to flow cells in a nanopore sequencing device from Oxford Nanopore Technologies, each flow cell comprising an array of transmembrane protein nanopores such as described herein, under control conditions and under conditions as disclosed herein.
  • the control conditions comprise potassium chloride, potassium ferrocyanide and potassium ferricyanide salts on both sides of the membrane.
  • the conditions as disclosed herein comprise a sodium salt on the cis and trans side of the membrane.
  • the melting temperature of the G-quadruplex from the thrombin-binding aptamer in the presence of different salts was determined by fluorescence measurements.
  • the 3’ and 5’ ends of a polynucleotide comprising a G-quadruplex structure were attached to a quencher and a fluorophore such that the fluorescence was quenched when the G- quadruplex was formed around the cation.
  • the quenching of the fluorophore was reduced ( Figure 4).
  • K 150 mM K Ferrocyanide, 150 mM K Ferricyanide, 25 mM K phosphate monobasic, pH 8.
  • Na 210 mM Na Ferrocyanide, 210 mM Na Ferricyanide, 25 mM Na phosphate monobasic, pH 7.
  • Na 150 150 mM Na Ferrocyanide, 150 mM Na Ferricyanide, 25 mM Na phosphate monobasic, pH 7.
  • the 3’ and 5’ ends of a polynucleotide comprising a G-quadruplex structure were attached to a quencher and a fluorophore such that the fluorescence was quenched when the G-quadruplex was formed around a cation. Raising the temperature results in denaturing of the G-quadruplex; the quenching of the fluorophore is then reduced (Figure 5).
  • the melting temperature of the G-quadruplex in the presence of potassium ions under the above conditions was determined to be approximately 75°C. In the presence of sodium ions the melting temperature of the G-quadruplex was determined to be approximately 65°C.
  • the melting temperature of the G-quadruplex was also shown to be concentration dependent with lower concentrations of cation leading to small variations in melting temperature (smaller than the ion to ion differences). Repeating the fluorescence assay in the presence of rubidium ions further lowered the melting temperature of the G-quadruplex to 55°C.
  • a sample comprising human genomic DNA was extracted from HG002 cells (Coriell) using a Puregene extraction kit (Qiagen), sheared using a Megaruptor (Diagenode), and size selected using a Pippin HT (Sage Science) to deplete the short fragment content and obtain a final library with a read length N50 of 30 kilobases.
  • This DNA sample was prepared for nanopore sequencing using Oxford Nanopore Technologies ligation sequencing kit SQK-LSK114. Following this preparation step, 500 ng of the sample was added to Oxford Nanopore Technologies PromethlON R10 flow cells, each flow cell comprising an array of transmembrane protein nanopores, under control and test conditions.
  • the control conditions comprised potassium chloride on the cis side of the membrane, and potassium ferrocyanide and potassium ferricyanide salts on the trans side of the membrane.
  • the test conditions comprised either rubidium or sodium salts on the trans side of the membrane with potassium chloride salts on the cis side of the membrane.
  • the following salt concentrations were used for the sodium and rubidium test conditions, respectively:
  • Example 3 The experiment described above in Example 3 was repeated using similarly extracted HG002 genomic DNA, this time sheared more intensely down to a read length N50 of 15 kilobases and prepared using Oxford Nanopore Technologies native barcoding kit (SQK-NBD114.24) for multiplexing samples. 500 ng of this DNA library was added to PromethlON RIO flow cells and run on MinKNOW version 5.9 with a standard sequencing script. Control flow cells were paused after 22 hours and washed with Oxford Nanopore Technologies wash kit (EXP-WSH004) before being reloaded with another 500 ng of the same 15 kilobase library and run for the remainder of the experiment.
  • EXP-WSH004 Oxford Nanopore Technologies wash kit
  • the EXP- WSH004 wash kit comprises a nuclease to digest and remove nucleic acid on the cis side of the membrane in the flow cell.
  • Figure 7A shows the total read output over time for this experiment, showing that the rubidium condition obtains similar total outputs despite not being washed and reloaded.
  • Figure 7B shows a graph tracking the channel loss over time for this experiment.
  • the slope of channel loss is representative of the decrease of available nanopore sequencing channels/throughput over time.
  • the control traces show clear recovery in the number of channels available at 22 hours after the wash protocol was carried out on the control flow cells.
  • the rubidium conditions show that the slope of channel loss is much shallower - believed to be due to the destabilisation of G-quadruplex structures in the trans chamber that would otherwise block channels - leading to longer retention of throughput.
  • the decrease in channel loss demonstrates that the presence of rubidium ions in the trans chamber enables the rubidium-containing flow cells to achieve a similar total sequencing output compared to the control flow cells, without the need for either the addition of more DNA library or for user interaction with the flow cell such as the use of a nuclease wash step.
  • Figure 8 A shows the total read output for this experiment comparing control flow cells to flow cells with rubidium salts in the trans chamber.
  • the rubidium condition shows an increase in total output of 46%.
  • This experiment demonstrates that the rubidium-containing flow cells were not adversely affected by the use of a nuclease wash step.
  • SEQ ID NO: 1 shows the amino acid sequence of (hexa-histidine tagged) exonuclease I (EcoExo I) from E. coli.
  • SEQ ID NO: 2 shows the amino acid sequence of the exonuclease III enzyme from E. coli.
  • SEQ ID NO: 3 shows the amino acid sequence of the RecJ enzyme from T. thermophilus (TthRecJ-cd).
  • SEQ ID NO: 4 shows the amino acid sequence of bacteriophage lambda exonuclease. The sequence is one of three identical subunits that assemble into a trimer. (htp://www.neb.com/nebecomm/products/productM0262.asp).
  • SEQ ID NO: 7 shows the amino acid sequence of Hel308 Mbu (Methanococcoides burtonii) helicase.
  • SEQ ID NO: 8 shows the amino acid sequence of the Dda helicase 1993 from Enterobacteria phage T4.
  • SEQ ID NO: 9 shows the nucleotide sequence of thrombin binding aptamer
  • a method of characterising a polynucleotide comprising:
  • the method comprises ejecting the polynucleotide from the first opening of the nanopore.
  • a method according to embodiment 7, comprising taking one or more measurements characteristic of the polynucleotides in the plurality of polynucleotides during the translocation of the portion of each polynucleotide through the nanopore, thereby characterising the polynucleotides.
  • the cation- mediated secondary structure is a guanine tetrad or a G-quadruplex, preferably a G- quadruplex.
  • the one or more conditions comprise a metal salt that disrupts the stability of the cation-mediated secondary structure.
  • the metal salt comprises a cation selected from the group consisting of Na + , Cs + , Li + , Mg 24- and Ca 2+ .
  • metal salt comprises sodium ferricyanide and/or sodium ferrocyanide.
  • polynucleotide, or each polynucleotide in the plurality of the polynucleotides has a length of 100 nucleotides or more.
  • a method according to any one of the preceding embodiments comprising controlling the movement of the or each polynucleotide with respect to the nanopore in the first direction using a polynucleotide-handling protein.
  • polynucleotide-handling protein is or comprises a helicase, translocase or helicase-nuclease complex.
  • the nanopore is a protein pore, a solid state pore or a DNA origami pore, preferably wherein the nanopore is a transmembrane protein pore.
  • the one or more characteristics comprises (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide and (v) whether or not the polynucleotide is modified.
  • ejecting the polynucleotide from the nanopore comprises applying a force across the nanopore.
  • a method according to any one of the preceding embodiments comprising applying a voltage potential across the nanopore via one or more platinum electrodes.
  • a kit for characterising a polynucleotide comprising:
  • An apparatus for characterising a polynucleotide comprising:

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés de caractérisation d'un polynucléotide pendant la translocation du polynucléotide à travers un nanopore. L'invention concerne également des procédés de fonctionnement d'un réseau de nanopores. L'invention concerne en outre des kits et des appareils pour mettre en oeuvre de tels procédés.
PCT/GB2024/051301 2023-05-18 2024-05-17 Procédé et produits pour caractériser un polynucléotide à l'aide d'un nanopore Pending WO2024236325A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024272217A AU2024272217A1 (en) 2023-05-18 2024-05-17 Method and products for characterizing a polynucleotide using a nanopore

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2307486.7A GB202307486D0 (en) 2023-05-18 2023-05-18 Method
GB2307486.7 2023-05-18

Publications (1)

Publication Number Publication Date
WO2024236325A1 true WO2024236325A1 (fr) 2024-11-21

Family

ID=86949208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2024/051301 Pending WO2024236325A1 (fr) 2023-05-18 2024-05-17 Procédé et produits pour caractériser un polynucléotide à l'aide d'un nanopore

Country Status (3)

Country Link
AU (1) AU2024272217A1 (fr)
GB (1) GB202307486D0 (fr)
WO (1) WO2024236325A1 (fr)

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576204A (en) 1989-03-24 1996-11-19 Consejo Superior Investigaciones Cientificas φ29 DNA polymerase
WO2000028312A1 (fr) 1998-11-06 2000-05-18 The Regents Of The University Of California Support miniature pour films minces contenant des canaux uniques ou des nanopores et procedes d'utilisation de ces derniers
WO2003003446A2 (fr) 2001-06-27 2003-01-09 President And Fellows Of Harvard College Controle de caracteristiques dimensionnelle a semiconducteurs
WO2006100484A2 (fr) 2005-03-23 2006-09-28 Isis Innovation Limited Administration de molecules dans une bicouche lipidique
WO2008102121A1 (fr) 2007-02-20 2008-08-28 Oxford Nanopore Technologies Limited Formation de bicouches lipidiques
WO2008124107A1 (fr) 2007-04-04 2008-10-16 The Regents Of The University Of California Compositions, dispositifs, systèmes, et procédés d'utilisation d'un nanopore
WO2009020682A2 (fr) 2007-05-08 2009-02-12 The Trustees Of Boston University Fonctionnalisation chimique d'ensembles de nanopores et de nanopores à semi-conducteurs, et leurs applications
WO2009035647A1 (fr) 2007-09-12 2009-03-19 President And Fellows Of Harvard College Capteur moléculaire haute résolution en feuille de carbone avec ouverture dans la couche de feuille de carbone
WO2009077734A2 (fr) 2007-12-19 2009-06-25 Oxford Nanopore Technologies Limited Formation de couches de molécules amphiphiles
WO2010062697A2 (fr) 2008-10-30 2010-06-03 Peixuan Guo Biocapteur à connecteur de protéine motrice d'encapsulation d'adn viral à intégration membranaire pour séquençage d'adn et autres utilisations
WO2010086602A1 (fr) 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Lieurs d'hybridation
WO2010122293A1 (fr) 2009-04-20 2010-10-28 Oxford Nanopore Technologies Limited Réseau de capteurs de bicouche lipidique
WO2012005857A1 (fr) 2010-06-08 2012-01-12 President And Fellows Of Harvard College Dispositif nanoporeux à membrane lipidique artificielle sur support de graphène
WO2012107778A2 (fr) 2011-02-11 2012-08-16 Oxford Nanopore Technologies Limited Pores mutants
WO2012164270A1 (fr) 2011-05-27 2012-12-06 Oxford Nanopore Technologies Limited Procédé de couplage
WO2013057495A2 (fr) 2011-10-21 2013-04-25 Oxford Nanopore Technologies Limited Procédé enzymatique
WO2013083983A1 (fr) 2011-12-06 2013-06-13 Cambridge Enterprise Limited Contrôle de la fonctionnalité de nanopore
WO2013098561A1 (fr) 2011-12-29 2013-07-04 Oxford Nanopore Technologies Limited Procédé de caractérisation d'un polynucléotide au moyen d'une hélicase xpd
WO2013098562A2 (fr) 2011-12-29 2013-07-04 Oxford Nanopore Technologies Limited Procédé enzymatique
WO2013153359A1 (fr) 2012-04-10 2013-10-17 Oxford Nanopore Technologies Limited Pores formés de lysenine mutante
WO2014013260A1 (fr) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Hélicases modifiées
WO2014064443A2 (fr) 2012-10-26 2014-05-01 Oxford Nanopore Technologies Limited Formation de groupement de membranes et appareil pour celle-ci
WO2014064444A1 (fr) 2012-10-26 2014-05-01 Oxford Nanopore Technologies Limited Interfaces de gouttelettes
WO2014135838A1 (fr) 2013-03-08 2014-09-12 Oxford Nanopore Technologies Limited Procédé d'immobilisation enzymatique
WO2014153625A1 (fr) 2013-03-25 2014-10-02 Katholieke Universiteit Leuven Biocapteurs de nanopores pour la détection de protéines et d'acides nucléiques
WO2015055981A2 (fr) 2013-10-18 2015-04-23 Oxford Nanopore Technologies Limited Enzymes modifiées
WO2015110813A1 (fr) 2014-01-22 2015-07-30 Oxford Nanopore Technologies Limited Procédé de fixation d'une ou plusieurs protéines de liaison de polynucléotides dans un polynucléotide cible
WO2015150786A1 (fr) 2014-04-04 2015-10-08 Oxford Nanopore Technologies Limited Méthode de caractérisation d'un acide nucléique double brin au moyen d'un nano-pore et de molécules d'ancrage aux deux extrémités dudit acide nucléique
WO2016034591A2 (fr) 2014-09-01 2016-03-10 Vib Vzw Pores mutants
WO2016055777A2 (fr) 2014-10-07 2016-04-14 Oxford Nanopore Technologies Limited Enzymes modifiées
WO2016059427A1 (fr) 2014-10-16 2016-04-21 Oxford Nanopore Technologies Limited Analyse d'un polymère
WO2016187519A1 (fr) 2015-05-20 2016-11-24 Oxford Nanopore Inc. Procédés et appareil pour la formation d'ouvertures dans une membrane à l'état solide au moyen d'un claquage diélectrique
WO2017098322A1 (fr) 2015-12-08 2017-06-15 Katholieke Universiteit Leuven Ku Leuven Research & Development Nanopores modifiés, compositions les comprenant et leurs utilisations
WO2017149318A1 (fr) 2016-03-02 2017-09-08 Oxford Nanopore Technologies Limited Pores mutants
WO2017203268A1 (fr) * 2016-05-25 2017-11-30 Oxford Nanopore Technologies Limited Procédé
WO2018011603A1 (fr) 2016-07-14 2018-01-18 Stefan Howorka Nanopores transmembranaires
US20180335417A1 (en) * 2015-12-24 2018-11-22 Hitachi High-Technologies Corporation Measuring reagent and analysis device for analyzing biopolymer
WO2019002893A1 (fr) 2017-06-30 2019-01-03 Vib Vzw Nouveaux pores protéiques
WO2019157424A1 (fr) 2018-02-12 2019-08-15 P&Z Biological Technology Llc Ensembles à nanopores et leurs utilisations
WO2019157365A1 (fr) 2018-02-09 2019-08-15 Ohio State Innovation Foundation Capteurs nanoporeux dérivés de bactériophages
WO2020025974A1 (fr) 2018-08-02 2020-02-06 Ucl Business Ltd Nanopores d'acides nucléiques liés à une membrane
WO2020025909A1 (fr) 2018-07-30 2020-02-06 Oxford University Innovation Limited Ensembles
WO2020074399A1 (fr) 2018-10-08 2020-04-16 Adolphe Merkle Institute, University Of Fribourg Ajustement à base d'oligonucléotides de peptides formant des pores pour augmenter la taille des pores, l'affinité membranaire, la stabilité et l'activité antimicrobienne
WO2020234612A1 (fr) 2019-05-22 2020-11-26 Oxford Nanopore Technologies Limited Procédé
WO2021255476A2 (fr) 2020-06-18 2021-12-23 Oxford Nanopore Technologies Limited Procédé
WO2021255475A1 (fr) * 2020-06-18 2021-12-23 Oxford Nanopore Technologies Limited Procédé de caractérisation sélective d'un polynucléotide à l'aide d'un détecteur

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576204A (en) 1989-03-24 1996-11-19 Consejo Superior Investigaciones Cientificas φ29 DNA polymerase
WO2000028312A1 (fr) 1998-11-06 2000-05-18 The Regents Of The University Of California Support miniature pour films minces contenant des canaux uniques ou des nanopores et procedes d'utilisation de ces derniers
WO2003003446A2 (fr) 2001-06-27 2003-01-09 President And Fellows Of Harvard College Controle de caracteristiques dimensionnelle a semiconducteurs
WO2006100484A2 (fr) 2005-03-23 2006-09-28 Isis Innovation Limited Administration de molecules dans une bicouche lipidique
WO2008102121A1 (fr) 2007-02-20 2008-08-28 Oxford Nanopore Technologies Limited Formation de bicouches lipidiques
WO2008102120A1 (fr) 2007-02-20 2008-08-28 Oxford Nanopore Technologies Limited Système de capteur bicouche lipidique
WO2008124107A1 (fr) 2007-04-04 2008-10-16 The Regents Of The University Of California Compositions, dispositifs, systèmes, et procédés d'utilisation d'un nanopore
WO2009020682A2 (fr) 2007-05-08 2009-02-12 The Trustees Of Boston University Fonctionnalisation chimique d'ensembles de nanopores et de nanopores à semi-conducteurs, et leurs applications
WO2009035647A1 (fr) 2007-09-12 2009-03-19 President And Fellows Of Harvard College Capteur moléculaire haute résolution en feuille de carbone avec ouverture dans la couche de feuille de carbone
WO2009077734A2 (fr) 2007-12-19 2009-06-25 Oxford Nanopore Technologies Limited Formation de couches de molécules amphiphiles
WO2010062697A2 (fr) 2008-10-30 2010-06-03 Peixuan Guo Biocapteur à connecteur de protéine motrice d'encapsulation d'adn viral à intégration membranaire pour séquençage d'adn et autres utilisations
WO2010086602A1 (fr) 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Lieurs d'hybridation
WO2010122293A1 (fr) 2009-04-20 2010-10-28 Oxford Nanopore Technologies Limited Réseau de capteurs de bicouche lipidique
WO2012005857A1 (fr) 2010-06-08 2012-01-12 President And Fellows Of Harvard College Dispositif nanoporeux à membrane lipidique artificielle sur support de graphène
WO2012107778A2 (fr) 2011-02-11 2012-08-16 Oxford Nanopore Technologies Limited Pores mutants
WO2012164270A1 (fr) 2011-05-27 2012-12-06 Oxford Nanopore Technologies Limited Procédé de couplage
WO2013057495A2 (fr) 2011-10-21 2013-04-25 Oxford Nanopore Technologies Limited Procédé enzymatique
WO2013083983A1 (fr) 2011-12-06 2013-06-13 Cambridge Enterprise Limited Contrôle de la fonctionnalité de nanopore
WO2013098561A1 (fr) 2011-12-29 2013-07-04 Oxford Nanopore Technologies Limited Procédé de caractérisation d'un polynucléotide au moyen d'une hélicase xpd
WO2013098562A2 (fr) 2011-12-29 2013-07-04 Oxford Nanopore Technologies Limited Procédé enzymatique
WO2013153359A1 (fr) 2012-04-10 2013-10-17 Oxford Nanopore Technologies Limited Pores formés de lysenine mutante
WO2014013260A1 (fr) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Hélicases modifiées
WO2014064443A2 (fr) 2012-10-26 2014-05-01 Oxford Nanopore Technologies Limited Formation de groupement de membranes et appareil pour celle-ci
WO2014064444A1 (fr) 2012-10-26 2014-05-01 Oxford Nanopore Technologies Limited Interfaces de gouttelettes
WO2014135838A1 (fr) 2013-03-08 2014-09-12 Oxford Nanopore Technologies Limited Procédé d'immobilisation enzymatique
WO2014153625A1 (fr) 2013-03-25 2014-10-02 Katholieke Universiteit Leuven Biocapteurs de nanopores pour la détection de protéines et d'acides nucléiques
WO2015055981A2 (fr) 2013-10-18 2015-04-23 Oxford Nanopore Technologies Limited Enzymes modifiées
WO2015110813A1 (fr) 2014-01-22 2015-07-30 Oxford Nanopore Technologies Limited Procédé de fixation d'une ou plusieurs protéines de liaison de polynucléotides dans un polynucléotide cible
WO2015150786A1 (fr) 2014-04-04 2015-10-08 Oxford Nanopore Technologies Limited Méthode de caractérisation d'un acide nucléique double brin au moyen d'un nano-pore et de molécules d'ancrage aux deux extrémités dudit acide nucléique
WO2016034591A2 (fr) 2014-09-01 2016-03-10 Vib Vzw Pores mutants
WO2016055777A2 (fr) 2014-10-07 2016-04-14 Oxford Nanopore Technologies Limited Enzymes modifiées
WO2016059427A1 (fr) 2014-10-16 2016-04-21 Oxford Nanopore Technologies Limited Analyse d'un polymère
WO2016187519A1 (fr) 2015-05-20 2016-11-24 Oxford Nanopore Inc. Procédés et appareil pour la formation d'ouvertures dans une membrane à l'état solide au moyen d'un claquage diélectrique
WO2017098322A1 (fr) 2015-12-08 2017-06-15 Katholieke Universiteit Leuven Ku Leuven Research & Development Nanopores modifiés, compositions les comprenant et leurs utilisations
US20180335417A1 (en) * 2015-12-24 2018-11-22 Hitachi High-Technologies Corporation Measuring reagent and analysis device for analyzing biopolymer
WO2017149318A1 (fr) 2016-03-02 2017-09-08 Oxford Nanopore Technologies Limited Pores mutants
WO2017149316A1 (fr) 2016-03-02 2017-09-08 Oxford Nanopore Technologies Limited Pore mutant
WO2017149317A1 (fr) 2016-03-02 2017-09-08 Oxford Nanopore Technologies Limited Pore mutant
WO2017203268A1 (fr) * 2016-05-25 2017-11-30 Oxford Nanopore Technologies Limited Procédé
WO2018011603A1 (fr) 2016-07-14 2018-01-18 Stefan Howorka Nanopores transmembranaires
WO2019002893A1 (fr) 2017-06-30 2019-01-03 Vib Vzw Nouveaux pores protéiques
WO2019157365A1 (fr) 2018-02-09 2019-08-15 Ohio State Innovation Foundation Capteurs nanoporeux dérivés de bactériophages
WO2019157424A1 (fr) 2018-02-12 2019-08-15 P&Z Biological Technology Llc Ensembles à nanopores et leurs utilisations
WO2020025909A1 (fr) 2018-07-30 2020-02-06 Oxford University Innovation Limited Ensembles
WO2020025974A1 (fr) 2018-08-02 2020-02-06 Ucl Business Ltd Nanopores d'acides nucléiques liés à une membrane
WO2020074399A1 (fr) 2018-10-08 2020-04-16 Adolphe Merkle Institute, University Of Fribourg Ajustement à base d'oligonucléotides de peptides formant des pores pour augmenter la taille des pores, l'affinité membranaire, la stabilité et l'activité antimicrobienne
WO2020234612A1 (fr) 2019-05-22 2020-11-26 Oxford Nanopore Technologies Limited Procédé
WO2021255476A2 (fr) 2020-06-18 2021-12-23 Oxford Nanopore Technologies Limited Procédé
WO2021255475A1 (fr) * 2020-06-18 2021-12-23 Oxford Nanopore Technologies Limited Procédé de caractérisation sélective d'un polynucléotide à l'aide d'un détecteur

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 2016, JOHN WILEY & SONS
CHARLES C HARDIN ET AL: "Thermodynamic and kinetic characterization of the dissociation and assembly of quadruplex nucleic acids", BIOPOLYMERS, JOHN WILEY, HOBOKEN, USA, vol. 56, no. 3, 8 November 2001 (2001-11-08), pages 147 - 194, XP071115132, ISSN: 0006-3525, DOI: 10.1002/1097-0282(2000/2001)56:3<147::AID-BIP10011>3.0.CO;2-N *
CHEN ET AL., NATURE COMMUNICATIONS, vol. 9, 2018, pages 1733
COLAS, MICRON, vol. 38, 2007, pages 841 - 847
GONZALEZ-PEREZ ET AL., LANGMUIR, vol. 25, 2009, pages 10447 - 10450
GUISET MISERACHS HELENA ET AL: "Distinct differences in metal ion specificity of RNA and DNA G-quadruplexes", JBIC. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, SPRINGER, DE, vol. 21, no. 8, 4 October 2016 (2016-10-04), pages 975 - 986, XP036093948, ISSN: 0949-8257, [retrieved on 20161004], DOI: 10.1007/S00775-016-1393-4 *
HERON ET AL., J. AM. CHEM. SOC., vol. 9, no. 5, 2009, pages 131
J. W. SHIM ET AL: "Single-molecule detection of folding and unfolding of the G-quadruplex aptamer in a nanopore nanocavity", NUCLEIC ACIDS RESEARCH, vol. 37, no. 3, 26 December 2008 (2008-12-26), pages 972 - 982, XP055092168, ISSN: 0305-1048, DOI: 10.1093/nar/gkn968 *
JONES ET AL., J. AM. CHEM. SOC, vol. 143, no. 22, 2021, pages 8305
KANKIAMARKY, J. AM. CHEM. SOC., vol. 123, 2001, pages 10799 - 10804
KIELLAND, J: "Individual activity coefficients of ions in aqueous solutions.", J. AM. CHEM. SOC., vol. 59, 1937, pages 1675 - 1678
LANGECKER, SCIENCE, vol. 338, 2012, pages 932 - 936
LEHNINGER, A. L.: "Biochemistry", 1975, WORTH PUBLISHERS, pages: 71 - 92
MARATHIASBOLTON, NUCLEIC ACIDS RESEARCH, vol. 28, no. 9, 2000, pages 1969 - 1977
MARUSIC ET AL., NUCLEIC ACIDS RESEARCH, 11 January 2012 (2012-01-11)
MONTALMUELLER, PROC. NATL. ACAD. SCI. USA., vol. 69, 1972, pages 3561 - 3566
PISELLI ET AL., EUR BIOPHYS J, vol. 51, 2022, pages 309 - 323
ROBERTSVELLACCIO: "The Peptides: Analysis, Synthesis, Biology", vol. 5, 1983, ACADEMIC PRESS, INC., pages: 341
SOSKINE ET AL., NANO LETTERS, vol. 12, no. 9, 2012, pages 4895 - 4900
WENDELL ET AL., NATURE NANOTECH, vol. 4, 2009, pages 765 - 772

Also Published As

Publication number Publication date
AU2024272217A1 (en) 2025-10-16
GB202307486D0 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
US12473595B2 (en) Coupling method
US20240240245A1 (en) Method
EP3097204B1 (fr) Procédé pour commander le mouvement d&#39;un polynucléotide traversant un pore transmembranaire
EP3126516B1 (fr) Procédé pour caractériser une molécule cible au moyen d&#39;un pore moléculaire
JP2023530155A (ja) ナノポアを通って移動するポリヌクレオチドを特徴付ける方法
EP4168582B1 (fr) Procédé de caractérisation sélective d&#39;un polynucléotide à l&#39;aide d&#39;un détecteur
AU2024272217A1 (en) Method and products for characterizing a polynucleotide using a nanopore
CN121195079A (zh) 用于使用纳米孔表征多核苷酸的方法和产品
US20230227902A1 (en) Method of repeatedly moving a double-stranded polynucleotide through a nanopore

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24731633

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024272217

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024272217

Country of ref document: AU

Date of ref document: 20240517

Kind code of ref document: A